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Down syndrome (DS) is the most common genetic form of intellectual disability. DS is a very 
complex genetic condition and is caused by trisomy of human chromosome 21. Studies mostly 
on human DS fetuses, plasma, fibroblasts, iPSCs, and mouse models of DS have demonstrated 
genome-wide dysregulation in genes and proteins involved in brain development and 
proteostasis. However, these studies were obtained with low-throughput technologies and 
addressed only either gene or protein level. Thus, it is still unknown how the gene 
dysregulation relates to protein dysregulation and, in turn, to DS brain deficits. Here, taking 
advantage of high throughput technologies, we explored in parallel both gene and protein 
levels on the same postmortem tissue from DS and age/sex-matched control individuals. We 
have revealed shared patterns of the transcriptome at gene and transcript levels and 
proteome dysregulation in hippocampus and cortex of DS individuals. We found many non-
triplicated genes and proteins differentially expressed along with overexpression in most of 
the triplicated genes and proteins. We identified many dysregulated biological processes in 
both brain regions, such as translation, axon development, synaptic signaling, neuron 
development, and mRNA splicing. We also found differentially expressed genes and proteins 
involved in extracellular vesicles and cell-substrate junction among all the cellular 
components identified in our study. In particular, our work highlights downregulation of 
neuronal genes together with downregulation of neuron-specific pathways such as long term 
potentiation (LTP) and synaptic vesicle cycle, and upregulation of microglia and astrocytic 
genes together with the increased response of inflammatory pathways such as complement 
and coagulation cascades and cytokine-cytokine receptor interaction, as key points in DS in 
both regions at gene and protein levels. Furthermore, we observed an alteration in RNA 
splicing in DS brains, which was shared across brain regions and involved many 
neurodevelopmental genes belonging to axon formation and guidance, dendrite 
morphogenesis, neurogenesis, and synaptic signaling. We show that genes related to axon 
formation and one of the RNA binding protein (PTBP2) that regulate these genes are 
differentially expressed and have differential splicing in DS brains. Interestingly, we collected 
the first experimental evidence (in murine neurons) of deficit in axonal polarization (multiple 
axon formation), establishing it as a definite phenotypic defect in DS. Finally, we performed 
small RNA sequencing on these postmortem human hippocampi and cortex and found several 
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differentially expressed miRNAs, which provides information about another layer of gene-
regulation in DS. Our findings indicate genome-wide dysregulation in adult DS hippocampus 
and cortex in a comprehensive assessment of both transcriptome and proteome. These data 
provide a unique and extensive resource for the field of DS. They will likely prove critical in 
identifying genetic drivers (among triplicated but also non-triplicated genes) to regulate 
complete biological systems at organelle-, cell-, process- or tissue-level to better understand 
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1.1. Neurodevelopmental disorders (NDDs): 
 
Neurodevelopmental disorders (NDDs) are diseases where development of brain structure 
and proper neural circuits are disrupted. Globally, NDDs correspond to >3% of health issues 
worldwide (Gilissen et al., 2014). NDDs share some common features such as learning and 
memory abnormalities, disrupted social and emotional aspects, immunological issues, and 
few comorbidities such as increased susceptibility to seizures (van Bokhoven, 2011). Some 
examples of NDDs are autism spectrum disorder (ASD), intellectual disability, fragile X 
syndrome, schizophrenia, and Down syndrome (Abrahams and Geschwind, 2008; van 
Bokhoven, 2011; Fromer et al., 2014; Geschwind, 2011; Matson and Shoemaker, 2009; 
Ropers, 2008). 
 
NDDs result from genetic factors (e.g., heterogeneous single-point mutations or polygenic 
(Niemi et al., 2018)) and environmental factors (e.g., maternal use of alcohol or drugs during 
pregnancy; preterm birth; exposure to environmental contaminants and socioeconomic 
status ((Cheroni et al., 2020; Heffernan and Hare, 2018; Tran and Miyake, 2017)). Identifying 
the causative genes for NDDs is highly important to understand the molecular mechanisms 
responsible for these disorders’ symptomatology. With this respect, the significant challenges 
are understanding how the genotype relates to the phenotype changes and pinpointing the 
key players involved in the disruption of physiological neuronal circuit formation.  
 
Despite tremendous technological advances to understand and map the whole brain by high-
throughput sequencing technologies, automated microscopy methods, and multi-electrode 
electrophysiological recordings, the understanding of the formation and function of the 
neuronal circuits of the brain is far from being completed. In particular, while these 
technologies have provided a new perspective on molecules and circuits responsible for the 
brain's functional and structural organization, understanding how dysregulation in the central 
nervous system (CNS) can lead to various NDDs is still in its infancy. To better understand 
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genetic disorders complexity, an integrative approach may be needed to assemble 
information from multiple perspectives. In particular, approaches that generate a high 
volume of in-depth data can transform the study of neurodevelopmental disorders because 
the diverse and complex genomic architecture of genetic disorders that begin early in life and 
through aberrant developmental trajectories have long-lasting consequences in adulthood. 
The underlying neuropathology, biological mechanisms, and the cells involved in many of the 
NDDs are largely unknown. A multi-omics approach in adulthood may, in fact, aid in finding 
the biological processes and pathways that are mostly dysregulated and responsible for NDD 
overt phenotypes. Then, we might even be able to find out which hub genes or cells or 
molecular network to target, to be able to regulate the whole system in one go for future 
therapeutic approaches. Thus, we took this multi-level data acquisition and interpretation 
approach to integrate transcriptomics and proteomics data from the same set of individuals 
to better understand a complex and multigenic neurodevelopmental disorder, Down 
syndrome. 
 
1.2. Down syndrome (DS): 
 
Down syndrome is a neurodevelopmental disorder caused by an extra copy of human 
chromosome 21 (HSA21). As for all neurodevelopmental disorders, DS is characterized by 
structural deficiencies in diverse brain regions such as the hippocampus, cerebellum, and 
cortex. These defects include hippocampal and cortical growth reduction, abnormal 
lamination, differentiation of neurons, abnormal synaptic plasticity, decreased dendritic 
branching, and spine density (Kazemi et al., 2016; Rachidi and Lopes, 2011). The reduced brain 
size and the other brain structural abnormalities are likely key players in DS people’s impaired 
cognition (Lott, 2012; Marin-Padilla, 1972; Suetsugu and Mehraein, 1980). Indeed, DS is the 
leading cause of intellectual disability worldwide. Cognitive impairment in DS ranges from 
mild to severe, and the intelligence quotient tends to go down with age. The cognitive defects 
start to emerge during infancy and keep increasing in early childhood with poor motor skills, 
speech, language acquisition, adaptive behavior, and cognition. Children with DS have a low 
ability to encode information and retrieve memories (Carlesimo et al., 1997; Contestabile et 
al., 2010; Roizen and Patterson, 2003; Sherman et al., 2007; Vicari et al., 2000). In addition to 
intellectual disability, people with DS suffer from craniofacial defects, congenital heart 
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defects (CHD), gastrointestinal abnormalities, hypotonia, audiovestibular and visual 
impairment, thyroid disorders, hematopoietic disorders, and leukemia, together with other 
dysfunction of immune responses (e.g., increased risk of infections, 
hematological/autoimmune disorders, and hyperactivation of the interferon (IFN) signaling) 
(Ana C. Xavier and Jeffrey W. Taub, 2010; Asim et al., 2015; Bull, 2011; Dey et al., 2013; 
Sherman et al., 2007; Sullivan et al., 2016). 
 
1.2.1. The genetics of DS: 
 
The genetic architecture of DS is extremely complex. The extra chromosome provides people 
with DS with extra copies of several genes. In humans, approximately 550 genes are located 
on HSA21, of which 222 encode proteins, and the rest encode microRNAs, long-noncoding 
RNAs, and other regulatory elements (Gupta et al., 2016). Since the trisomy of chromosome 
21 causes DS, theoretically, one would expect that genes on chromosome 21 are present in 
three copies and have 1.5 fold more expression in people with DS compared to the euploid 
state. However, indeed, this is not the case.  
There are two hypotheses to explain the effect of the extra chromosome in the DS phenotype. 
The first is known as the gene-dosage effect hypothesis, where one of the triplicated genes 
can (directly or indirectly through the effect on the downstream signaling pathways) affect 
the tendency to acquire severe cognitive defects. For example, APP, a triplicated gene, 
increases susceptibility to early-onset Alzheimer's disease (AD). A second hypothesis is a 
developmental instability, which implies that the presence of extra-chromosome causes 
global, non-specific disturbances in gene expression (independently of what the triplicated 
genes encode for), disrupting biological homeostasis.  
Over the last two decades, it has been conclusively demonstrated that the differentially 
expressed genes are not just located on HSA21 but also on other chromosomes as well, 
suggesting that both gene dosage hypothesis and a broad dysregulation of gene expression 
in DS are involved (Araya et al., 2019; Letourneau et al., 2014; Lockstone et al., 2007). In 
particular, Letourneau et al. have reported that Down syndrome is associated with altered 
gene expression across every chromosome and not just chromosome 21. They performed 
transcriptomics of fetal fibroblasts from a pair of monozygotic twins discordant for trisomy 
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21 (Letourneau et al., 2014). Another study where the authors performed a meta-analysis on 
various human samples (tissues such as the brain, thymus; cells such as blood cells, 
fibroblasts, and iPSCs) from DS and healthy individuals found that dysregulated genes (both 
triplicated and non-triplicated) had a 1.5 times differential expression (Pelleri et al., 2018). 
Overall, DS symptoms originate from gene-expression disturbances. Thus, to design new 
therapeutic approaches, it becomes vital to investigate the molecular mechanisms behind the 
phenotypic consequences resulting from these genetic alterations. 
1.2.2. Mouse models of DS: 
 
The elucidation of human and mouse genomes and their comparative analysis has revealed 
that the long arm of HSA21 is homologous to portions of three mouse chromosomes 
(MMU17, MMU16, and MMU10). One of the most extensively studied mouse model of Down 
syndrome (the Ts65Dn mouse) carries a large segment of mouse chromosome 16 (~110 
HSA21 ortholog genes) along with a substantial segment of MMU17 (60 centromeric genes) 
not syntenic to HSA21 (Duchon et al., 2011). The chromosomal triplication in Ts65Dn mice is 
carried as an additional freely segregating chromosome generated by cesium irradiation. 
Thus, Ts65Dn correlates well with aneuploidy observed in individuals with DS and can be used 
to investigate both the gene-dosage hypothesis and the developmental instability hypothesis. 
In other models (e.g., Ts1Cje, Dp(16)1/Yey, Dp(17)1Yey, and Dp(10)1Yey), the triplication is 
not characterized by a freely segregating chromosome. Ts1Cje was generated via reciprocal 
translocation of the distal portion of mouse chromosome 16 onto chromosome 12, resulting 
in 71 HSA21 ortholog genes. Dp(16)1/Yey contains ~130 genes, orthologous to HSA21, on the 
distal portion of mouse chromosome 16 via Cre-mediated recombination and contains the 
largest HSA21 orthologous genes. At the same time, Dp(17)1Yey and Dp(10)1Yey carry the 
MMU17 and MMU10 syntenic regions, respectively, with fewer orthologous genes (Li et al., 
2007). 
1.2.3. Transcriptomics and proteomics studies in DS:  
 
Even though the cause for DS has been known for many decades now, and we also know that 
both triplicated and non-triplicated genes are largely dysregulated, we still do not know the 
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precise mechanisms by which triplication of HSA21 genes leads to neuroanatomical and 
neurobehavioural phenotypes in DS individuals. Moreover, even with the advancements in 
high throughput technologies, there are very few studies at transcriptome and proteome 
levels in DS individuals.  
At the transcriptome level, there is only a single study by Olmos-Serrano et al. where the 
authors uncovered defective oligodendrocyte differentiation and myelination after 
performing transcriptional profiling in postmortem brains from DS individuals, spanning from 
mid-fetal development to adulthood (Olmos-Serrano et al., 2016). The authors also validated 
their results via cross-species comparison to the Ts65Dn mouse model. However, this study 
has been performed using outdated technology, microarray, which requires transcript 
specific probes and is not very high throughput.  There are few other studies on human-
derived tissues or cells performed using microarrays, but they are done either on fetal tissues, 
amniotic fluid, fibroblasts, or iPSC-derived neurons (Gonzales et al., 2018; Guedj et al., 2016; 
Huo et al., 2018; Stamoulis et al., 2019; Waugh et al., 2019). For example, Gonzales et al. 
identified significant changes in the transcript expression and changes in alternative splicing 
and repetitive element transcripts associated with chromosome 21 trisomy. Also, their 
transcriptome data suggested that trisomy of chromosome 21 may interfere with the 
maintenance of pluripotency. Another study on iPSCs-derived GABAergic interneurons from 
DS individuals indicated migration defects from their RNA sequencing data (Huo et al., 2018). 
Here, the authors transplanted the iPSCs derived GABAergic progenitors from trisomic and 
euploid control lines into SCID mouse brain in the medial septum. They observed that the 
neurites from trisomic interneurons were shorter and with fewer branches, and the majority 
of these cells were immature and had migration defects. 
In animal models, we could find only one study where recently Aziz at el. compared brain 
development, gene expression, and behavior in three different mouse models of Down 
syndrome and found Ts1Cje and Ts65Dn brains had considerably more differentially 
expressed genes compared with Dp(16)1/Yey mice. Differentially expressed genes showed 
little overlap in identity and chromosomal distribution in the three models, leading to 
dissimilarities in affected functional pathways. The authors concluded with unique limitations 
of each model of Down syndrome (Aziz et al., 2018). 
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Interestingly, only a few studies have explored the non-coding RNAs, especially microRNAs. 
For example, Perez-Villareal et al. have profiled the blood samples from DS people and have 
in detail checked the miR-155 and let-7c, which are encoded on HSA21 and are overexpressed 
in DS. They found that these differentially expressed miRNAs regulate genes involved in lipid 
metabolism and nervous system development (Pérez-Villareal et al., 2020). In another study 
from 2018, the authors used nanoparticle formulations to analyze a subset of miRNAs in the 
plasma of young DS people and their siblings. They found many of them to be differentially 
expressed (Salvi et al., 2019). 
Interestingly, in a study done on lymphocytes from children with DS, it was observed that not 
all triplicated miRNAs were upregulated, and other differentially expressed miRNAs were 
located outside chr21 (Xu et al., 2013). Five microRNAs (miR-99a, miR-155, miR-802, miR-
125b-2, and let-7c) from chromosome 21 were detected to be overexpressed in DS; these 
miRNAs had an expected ratio of 1.5 vs. controls. In a very recent study in 2019, miRNAs’ 
altered expression has been observed in the plasma obtained from mothers with fetal DS. 
The authors found 13 miRNAs to be differentially expressed, and targets for these 
differentially expressed miRNAs were involved in CNS development, congenital 
abnormalities, and heart defects (Zbucka-Kretowska et al., 2019). 
At the proteomic level, there are some studies on the fetuses, amniocytes, plasma, and 
fibroblasts derived from DS individuals (Lanzillotta et al., 2020; Liu et al., 2018, 2017; O’Bryant 
et al., 2020). For example, in a study on amniocytes and amniotic fluid, the authors found 
around 904 differentially expressed proteins involved in 25 biological pathways after 
proteomics analysis. In the top two pathways, they found NF-kB and the other one, APP, 
which are known DS dysregulated genes. They further validated nine proteins with selected 
reaction monitoring (SRM) assays to quantitate individual amniocyte samples differential 
expression. Two proteins (SOD1 and NES) showed consistent differential expression across 
the samples (Cho et al., 2013).  Proteomics studies on DS fetuses started with the work of 
Opperman et al., in which the authors showed 84% homology between the proteins 
expressed in DS and control samples, and ones that were differentially expressed were known 
to have a structural role that was consistent with defects in DS brain development 
(Oppermann et al., 2000). A more comprehensive study by Cheon et al. led to the 
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identification and quantitation of ten protein spots that were differentially expressed, and 
these were also involved in defective brain development (Cheon et al., 2001). Cheon et al. 
followed up with few more studies in DS fetuses, and they showed many altered protein 
pathways such as impairment of synaptic plasticity, brain development, and energy 
metabolism (Sun et al., 2011). 
On the other hand, we found one only study at the proteome level on young adult human DS 
brains. In the cerebral cortex from young DS adults and age-matched controls, the authors 
found protein carbonylation, which is the oxidation of protein residues by reactive oxygen 
species in DS individuals. They showed this effect on six proteins that are part of the 
intracellular quality control system leading them to hypothesize the proteostasis network's 
impairment (Di Domenico et al., 2013). 
In animal models,  changes in protein expression level were observed in the hippocampus and 
cerebellum of the Ts65Dn mouse model at the age of 6 and 12 months after proteomic 
analysis (Vacano et al., 2018). Notably, the authors observed minimal differences in protein 
expression between disomic and trisomic groups but identified numerous differences 
associated with age and brain region. Ahmed et al. also showed similar findings in three brain 
regions, hippocampus, cortex, and cerebellum, in the Ts65Dn mouse model, suggesting that 
with age, the protein expression dysregulation is more exacerbated in 12 vs. 6 months old 
animals. They also observed that the dysregulated proteins were involved in mTOR and MAPK 
pathways (Ahmed et al., 2017).  
There is only one study in which both transcriptomics (with RNA-seq) and proteomics (LC-
MS/MS) has been done on the same samples. Here, the authors generated iPSCs and induced 
them towards neuronal lineage to perform differential expression analysis and study the 
temporal dynamics of dysregulated genes.  They compared their gene expression data with 
data from BrainSpan (Miller et al., 2014), which contains developing human brain 
transcriptome information from RNA sequencing and microarray experiments. The authors 
observed that RNA-seq profiles of differentiated neural progenitors exhibited similarly to the 
developing brain at 20-30 weeks post conception. At both gene and protein levels, the 
authors found dysregulation in DNA replication, pluripotency, synaptic formation, and neural 
signaling in neural progenitor cells. When the progenitors were differentiated at later stages 
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of development, they saw a deficit in TGF-b signaling and SMAD-associated signaling (Sobol 
et al., 2019).  
The efforts mentioned above have generated a large amount of data. They have provided 
much-needed clues and potential target candidates to go forward with the research in DS to 
develop novel therapeutics. However, most of the findings are originating from mouse 
models, and these observations may not translate well in humans. Indeed there may be 
disparity due to i) failure of the animal models to accurately mimic the human disease 
condition; ii) the fact that most of the animal models most likely replicate specific processes, 
but not the whole spectrum of the physiological changes that are present in humans; iii) 
identified biomarkers between the two species might not be similar and iv) inter-individual 
genetic variation affects the human gene expression, which cannot be replicated in the mouse 
models. Also, a large discrepancy remains in how well the transcriptome level's expression 
profiles match with those at the protein level, posing some questions on what biological 
processes are the most responsible for the DS phenotype and what should be considered with 
the highest priority for developing treatments for DS.  
Moreover, the knowledge from studies in humans mainly originates from fetal tissues, 
plasma, fibroblasts, and iPSCs. We do not still understand how well they correspond to the 
adult human DS condition. Integration of both transcriptome and proteome to study genes, 
miRNAs and proteins in the same set of samples would provide an excellent opportunity to 
understand the human DS condition at a substantially higher resolution.  
Although I have taken an unbiased approach in addressing the impact of trisomy 21, I briefly 
introduce one of the aspect of DS: neuroinflammation, as a part of my contribution to a 
published manuscript (Pinto et al., 2020). 
1.2.4. Neuroinflammation: 
 
Neuroinflammation is a multistep phenomenon controlled by resident glial immune cells 
(mainly microglia and astrocytes) (Norden et al., 2016) and a cascade of pro-inflammatory 




Microglia are the resident immune cells in CNS. These represent 5-20% of the human brain 
cells and have a ramified morphology in healthy condition (Butovsky and Weiner, 2018). 
Microglia plays a significant role in brain development and plasticity (Arcuri et al., 2017; 
Tremblay et al., 2011). They sculpt the neuronal circuit by synaptic pruning (Schafer and 
Stevens, 2013), regulate neuronal death, and phagocytose neuronal progenitors (Kaur et al., 
2017; Mosher et al., 2012). They also give support to axonal growth and phagocytose debris 
(Tay et al., 2018). Critical period plasticity and activity-dependent synaptic maturation are 
also regulated by microglia activity (Miyamoto et al., 2016; Paolicelli et al., 2011; Squarzoni 
et al., 2015). In disease or during an infection, microglia adopt an amoeboid-like shape and 
engage in pro-inflammatory immune responses at the site of infection or injury (Pinto et al., 
2020; Salter and Stevens, 2017). During inflammation, microglia upregulate activation and 
phagocytic markers and produce pro-inflammatory cytokines (Arcuri et al., 2017; Hanisch and 
Kettenmann, 2007; Shobin et al., 2017; Sipe et al., 2016). 
 
Astrocytes represent around 25-50% of CNS cells. They are neuro-supportive, control brain 
homeostasis (e.g., control pH and oxidative stress) and are responsible for proper neuronal 
function (e.g., synaptic plasticity) (Liddelow and Barres, 2017; Sochocka et al., 2017; 
Verkhratsky et al., 2013). Like microglia, astrocytes also become reactive and contribute to 
death of neurons (Liddelow et al., 2017). 
 
Microglia and astrocytes communicate with each other either through secreted factors or 
cell-cell contact. Microglia can make the astrocytes reactive upon release of specific cytokines 
during diseased states, and in turn, astrocytes can control the functions of microglia by 
sequestering cholesterol (Liddelow et al., 2020).  
 
1.2.4.1. Neuroinflammation in DS and other brain diseases: 
 
Hemostasis between the CNS and peripheral nervous system fails during pathological 
conditions, leading to prolonged activation of glial cells, production of pro-inflammatory 
factors, and reactive oxygen species. Multiple sclerosis (MS) is the most prominent brain 
disorder which results from CNS inflammation. Advances in understanding the inflammatory 
mechanisms in MS have made it possible to design therapies that could reduce 
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neuroinflammation. Similarly, autoimmune diseases such as systemic lupus erythematosus, 
limbic encephalitis, and others have responded to a treatment designed with the help of 
studies done in MS. Other diseases with neuroinflammatory response include epilepsy 
(Vezzani et al., 2019), cerebral ischemia resulting in stroke (Stoll and Nieswandt, 2019), 
migraine (Edvinsson et al., 2019), and neurodegenerative diseases such as Frontotemporal 
dementia (FTD) (Yoshiyama et al., 2007), Alzheimer’s disease (AD) (Calvo-Rodriguez et al., 
2020; Sokolova et al., 2009), Parkinson’s disease (PD) (Lecours et al., 2018), and Amyotrophic 
lateral sclerosis (ALS) (Béland et al., 2020).  Interestingly, in neurodevelopmental disorders 
such as autism spectrum disorder (ASD) and schizophrenia, several studies have pointed to 
neuroinflammation with the result of microglial and astrocytic activation (Laurence and 
Fatemi, 2005; Li et al., 2009; Morgan et al., 2010; Vargas et al., 2005).  
 
As already highlighted above, neuroinflammation in DS is very prevalent (Wilcock and Griffin, 
2013; Wilcock et al., 2015).  A Role of microglia in DS was first reported in 1989, where the 
authors showed elevated expression of IL-1 in microglia and astrocytes in DS individuals. 
Other studies have been performed in brain samples from people with DS and mouse models   
(Griffin et al., 1989). Interestingly, in DS fetuses, an increase in microglia number and 
increased infiltration of macrophages in the CA1 and subiculum region of the hippocampus 
has been observed (Kanaumi et al., 2013; Wierzba-Bobrowicz et al., 1999).  
 
In recent studies, an increase in the inflammatory response (including interferon-stimulated 
genes), differential expression of inflammation-related proteins, and activation phenotype of 
microglia and astrocyte have been reported in DS individuals (Pinto et al., 2020)*; Wilcock et 
al., 2013; Wilcock et al., 2015). Microglia activation led to dendritic spine defects in the 
Ts65Dn mouse (Pinto et al., 2020)*. Another study that showed increase induction of 
interferon-stimulated genes was performed in fibroblasts and blood cells from DS people with 
the help of transcriptome analysis (Sullivan et al., 2016), which also confirmed the previous 
results  (Tan et al., 1974). Sullivan et al. followed up on their previous study to confirm chronic 
autoinflammation in DS in plasma by performing proteomics analysis. They found elevated 
levels of IL-6, TNF- α, and MCP-1, the potent inflammatory cytokines linked to IFN signaling 
(Sullivan et al., 2017). Mass cytometry also revealed a similar global immune remodeling level 
with a signature increase in interferon type I response in DS (Waugh et al., 2019). Two recent 
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studies have also reported therapies to inhibit and block the microglia activation and reduce 
the neuroinflammation in mouse models of DS (Pinto et al., 2020; Tuttle et al., 2020). 
 
* Pinto et al. measured the effect of microglial activation on cognitive functions in two mouse models of DS 
(Dp(16)1Yey and Ts65Dn) and observed microglia activation in the human DS hippocampus. The authors 
observed an increase in the cell soma and decreased branches for the microglia in both the models and the 
human brain samples. The mouse models showed a decrease in spine density and electrophysiological activity 
in the hippocampal neurons. They also observed deficits in hippocampus-dependent cognitive tasks in the 
mouse models. With the help of acetaminophen, an anti-inflammatory drug, the authors could rescue the 
cognitive deficits, microglial morphology, and spine density defects in young adult animals. For this study, I 
performed RNA-seq analysis on human hippocampal samples from DS and control individuals.  I found that the 
upregulated genes were involved with immunological pathways and glial cells (astrocytes, microglia, and 
oligodendrocytes), while the downregulated genes were enriched in neurological pathways and neuronal cells. 
Please, find the complete manuscript in the appendix at the end of the thesis. 
 
1.2.5. Pharmacological treatments: 
 
There is currently no pharmacological treatment to rescue cognitive impairment in DS people. 
Nevertheless, early educational interventions and environmental enrichment lead to an 
improvement in cognitive tasks and intellectual disability scores in DS children (Engevik et al., 
2016; Martínez-Cué et al., 2005). However, these strategies are of limited use in adults with 
DS as the cognitive decline progresses with age and they lose the acquired abilities (Couzens 
et al., 2011, 2012). 
 
Interestingly, various drug treatments targeting various putative molecular pathways are 
effective in rescuing cognition in DS animals. While these preclinical studies performed in 
different mouse models of DS have reported improvement in cognitive deficits in the models, 
the same drugs have failed to replicate all the good and promising effects when administered 
to people with DS during clinical trials. This could be due to genetic differences between 
mouse and human and to safety, efficacy, compensatory mechanisms, the timing of 
intervention, or the drug's dosage . 
 
These are some of the main reasons that we need approaches that could identify molecular 
targets from perspectives that take a more global approach to design therapeutics that are 
highly effective in humans. One possible way of addressing this issue is with high throughput 
technologies such as transcriptomics and proteomics.   
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1.3. The rationale and the questions: 
 
DS is a very complex disorder with global gene dysregulation. Thus a fundamental question in 
DS is to know what is the impact of the triplication of chromosome 21 on this global gene 
dysregulation and how does these profound changes at the genetic level translate to 
phenotypic changes in DS individuals. To understand the genotype to phenotype connection, 
we need to integrate unbiased, high throughput information at gene and protein levels. In 
the past, most studies have reported their findings using technologies (i.e., microarrays, serial 
analysis of gene expression (SAGE), selected reaction monitoring assay (SRM), and gel-based 
proteomics) that are biased and not high throughput. This is because, until the last five years, 
performing high throughput transcriptomic and proteomic studies were too costly and slow. 
Moreover, there were considerable limitations in the availability of postmortem brains. Thus, 
most of these studies were performed on fetal tissues, plasma, fibroblasts, iPSCs derived from 
DS individuals and mouse models. Recently, with the advent of better technologies, reduction 
in cost and increase in speed, and the availability of computational methods to analyze the 
data obtained from high throughput technologies, along with ongoing efforts to create large 
brain biobanks, it has become possible to perform multiple analysis on the same set of 
samples. Here, I will take an integrative high throughput approach to perform a 
comprehensive assessment of adult DS individuals transcriptome and proteome to find hub 
genes and proteins that could target future therapeutics. 
 
Below, I introduce some of the concepts involved in the study, such as gene expression, RNA-
protein correlation, co-expression of genes, alternative splicing, and miRNAs. 
 
1.4. Gene expression: 
 
Gene expression is a complex process that involves the conversion of DNA to RNA 
(transcription), post-transcriptional regulation, conversion of RNA to protein (translation), 
and post-translational modifications. Transcription is controlled by transcription factors, 
chromatin modifications, splicing, polyadenylation, transport, and degradation.  Translation 
involves initiation, elongation, and termination, as well as localization and degradation. The 
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interaction between multiple gene products (proteins) converts this genotype to phenotypic 
information (Buccitelli and Selbach, 2020). 
 
1.4.1. Coding and non-coding genes: 
 
The mammalian genome is transcribed into multiple RNAs that can be grouped into coding 
and non-coding RNAs. Protein coding genes are mature RNA species that are translated to 
form a protein product. Non-coding RNAs do not code for any protein product. These non-
coding RNAs are of multiple types based on their biosynthesis and length, such as lncRNAs, 
miRNAs, and pseudogenes. lncRNAs are long non-coding RNAs of more than 200 bp. They do 
not translate, but they fine-tune the gene expression. miRNAs are 21-22 nucleotides in length 
and bind the 3’ untranslated region of the mRNA, regulating gene expression. Pseudogenes 
are those regions of the genome that are non-functional and contain defective copies of 
protein-coding genes due to the accumulation of mutations during evolution (Beermann et 
al., 2016; Dykes and Emanueli, 2017; Li and Liu, 2019).  
 
1.4.2. Transcriptomics:  
 
A gene is transcribed into multiple transcripts, and the entire set of transcripts originating 
from an organism is known as the transcriptome of that species. The high throughput 
sequencing of all the transcript isoforms for all the genes is known as RNA sequencing. For 
convention, the difference between two groups is known as differential gene expression 
(DGE) when the gene counts are accumulated from all the transcript counts for that gene. 
Also, for the convention, differential transcript expression (DTE) is instead the difference in 
transcript expression between two groups when the diverse type of transcript counts are 
taken into consideration (Figure 1.1). A differentially expressed gene can have transcripts 
where only a few of them are differentially expressed, as illustrated in Figure 1.1B (i) & (ii), 
where Gene A is DGE, but only transcript A.2 is differentially expressed. 
 
On the other hand, it is also possible for a gene to be not differentially expressed but has all 
its transcripts being differentially expressed between the two groups, as shown in the Figure 
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1.1B (i) & (ii), where Gene B is not DGE, but all its transcripts (Transcript B.1 and B.2) are 
differentially expressed. RNA sequencing is used to assess both gene and transcript level 
abundances. In summary, gene-level abundance is the sum of all transcript-level abundance. 
 
 
Figure 1.1. Definitions of different types of differential expression analysis. In panel A), two genes (Gene A and 
Gene B), with 3 and 2 transcripts, are shown. In panel B) the expression of these two genes with their transcripts 
is compared across two conditions (Condition 1 and Condition 2). The horizontal width of each colored box 
represents the abundance of the relevant gene or transcript. A negative differential expression result (red cross-
mark) for a given entity in any one of the two analysis types does not exclude that same entity from having a 
positive result (green tick-mark) in one of the other two analysis types. DGE: Differential gene expression, DTE: 
Differential transcript expression (Froussios et al., 2019; Newman et al., 2018).  
 
In general, the RNA sequencing workflow involves RNA extraction, mRNA enrichment or 
ribosomal RNA depletion, preparation of cDNA, and addition of unique adapter sequences to 
each sample to generate sequencing libraries. All the sample libraries are then pooled 
together to generate a nanomolar pool (this process is called multiplexing) and sequenced at 
a depth of 10-100 million reads. Following sequencing, the data is demultiplexed, where the 
sample reads are separated based on unique adapter sequences attached to each sample. 
Subsequently, they are computationally aligned to the reference genome, and counts for each 
gene/transcript in each sample is computed. The counts are then filtered and normalized 
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between samples, and a statistical method is applied to estimate differential gene/transcript 
expression between sample groups (Stark et al., 2019).  
 
Specifically, mRNA sequencing involves the enrichment of oligo-dT sequences, which contain 
poly-adenylated (poly(A)) tails and focuses only on protein-coding sequences. For obtaining 
non-coding RNAs and transcript-level information, ribosomal RNA (rRNA) deletion is required. 
rRNA-depleted RNA sequencing generates information for both protein-coding genes and 
some non-coding genes. rRNA-depleted whole transcriptome sequencing is also compatible 
with degraded samples such as those obtained from humans, as they usually suffer 
postmortem interval. Small RNAs require their targeted sequencing, where only the diverse 
class of small RNAs such as microRNA, small nuclear RNAs (snRNAs), transfer RNAs (tRNAs), 
and small nucleolar RNAs (snoRNAs) are queried (Hafner et al., 2008). For improving the 
analysis of degraded samples, a higher sequencing depth is required, which reduces the bias 
between the samples. By taking this approach, it is possible to measure protein-coding genes, 




Mass spectrometry (MS)-based proteomics is used to identify and quantify proteins at a large 
scale, without the use of antibodies (Aebersold and Mann, 2016). MS measures the mass to 
charge ratio and intensity of charged particles. Proteomics can be used in an unbiased manner 
to investigate individual proteins and their functions.  
 
Proteins are extracted from the cells or tissues of interest by enzymatic digestion. The 
resulting peptides are then separated on high-performance liquid chromatography columns, 
which are packed with micrometer-sized beads and run at nanoliter flow rates. Mass and 
intensity of peptides are measured in mass spectrometer scans. The peptides are identified 
by comparing the fragments or MS/MS spectra to a standard database of peptides (Manzoni 




1.4.4. Correlation between mRNA and protein: 
 
Mostly, gene expression is associated with mRNA expression, and it is generally assumed that 
mRNA expression can be considered a proxy for protein expression. Nevertheless, 
transcription involves multiple post-transcriptional steps, which result in the generation of 
not one but many mRNA isoforms. These, in turn, form multiple protein products. 
Accordingly, at the level of high-throughput technologies such as RNA sequencing  (Stark et 
al., 2019) and proteomics (Aebersold and Mann, 2016), the protein expression does not 
coincide well with mRNA expression.  
 
The relationship between mRNA and protein expression levels is usually studied at mRNA-
protein correlation. This correlation is of two types: a) across-gene correlation explores how 
well the abundance of mRNAs correlates with their corresponding proteins for different genes 
in the same condition; b) while within-gene correlation inquires how much the change in 
mRNA level of one gene can explain the change in corresponding protein level across 
conditions. Across-gene correlations for mammalian tissues range around 0.6, but these could 
be higher or lower due to variations in technical biases. Within-gene correlation reveals a 
significant but modest correlation between mRNA and protein, provided that we look at the 
genes with similar functional identity to carry out this correlation (Buccitelli and Selbach, 
2020).  
 
Both RNA sequencing and MS-based proteomics suffer from noise and biases, which affect 
both precision and accuracy (Aebersold and Mann, 2016; Stark et al., 2019). Technical and 
biological noise could be estimated and reduced by incorporating more samples in the study. 
On the other hand, bias is difficult to quantify precisely but could be estimated approximately 
by adding reference RNAs or proteins (Schwanhäusser et al., 2011).  
 
On average, expressed genes are present at less than one mRNA copy per cell, whereas the 
protein abundance is at 108 molecules per gene. The difference of several magnitudes in the 
dynamic range of mRNA and protein expression is mainly due to higher translation efficiencies 
for more abundant proteins (Li et al., 2014a). Equally important is the speed of transcription 
and translation. Transcription usually takes about 1 hour to generate ~100 mRNA from the 
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DNA template, while 106 protein molecules are generated after transcription initiation in 
more than one hour from a single locus (Hausser et al., 2019). So, translation and protein 
degradation are on-demand and context-specific to reduce the time for protein production 
or downregulation (Schwanhäusser et al., 2013). Overall, protein abundance is dependent on 
four critical parameters: rate of transcription, mRNA half-lives, translation rate, and protein 
half-lives (Baum et al., 2019; Hausser et al., 2019; Kristensen et al., 2013). 
 
1.4.5. RNA sequencing or proteomics: Which one to do? 
 
It depends on the specific question that we would want to address. The gene expression level, 
mRNA hence RNA-seq, is closer to the genome and would reflect transcription and RNA 
processing events. In contrast, protein or proteomics looks at the next stage in gene 
expression, which is related to phenotype. With RNA-seq, it is possible to get information 
about all the mRNAs as it provides a complete picture of the cell or tissue of interest. 
Simultaneously, proteomics can inform about less number of proteins as not all the mRNAs 
have been translated or available as protein products in that particular spatial, temporal 
context (the time the cells or tissues are collected). Protein is more stable than mRNA, and 
the post-transcriptional and translational effects can only be studied at the protein level and 
are not visible at the mRNA level (Buccitelli and Selbach, 2020). On the other hand, 
proteomics outperforms transcriptomic studies at the level of functional predictions as 
observed from many co-expression studies (Kustatscher et al., 2019; Lapek et al., 2017; Ori et 
al., 2016; Romanov et al., 2019; Wang et al., 2017).  
 
Both mRNA and protein expression provide unique information about the biological system 
in question. Thus, it is essential to integrate RNA sequencing and proteomics technologies to 
better understand gene expression principles in physiological and pathological conditions. 
The flow of information from the genome to phenotype regulated at multiple levels will 
benefit from the acquisition and integration of multi-omics datasets. This would provide 






The brain is a complex organ consisting of billions of neurons that make trillions of 
connections among themselves (Koch and Laurent, 1999). This complex network executes 
various high function processes and behaviors, including cognitive processes such as learning 
and memory (Kandel, 2001). Understanding this complexity is one of the most challenging 
aspects of neuroscience. The perturbations taking place at molecular, cellular, and network-
level in developmental disorders make it even more of a priority.  
 
The rapid developments in technologies such as transcriptomics and proteomics have 
provided essential insights into CNS development and function (McCarroll et al., 2014; Shin 
et al., 2014). Acquiring data at multiple biological levels has provided a more comprehensive 
view of gene-expression regulation than any single omics. The development of methods to 
integrate multi-omics data has provided capabilities to carefully and systematically interpret 
results and make relationships among the data. 
 
Multi-omics is an integration of data acquired using multiple single omics technologies on the 
same set of samples to understand the flow of information at multiple levels (Hasin et al., 
2017). Each omics provide a different set of information to characterize the normal and 
diseased condition at a functional level. The integration allows looking for a causative 
signature rather than a readout at a single omics level. A key challenge in multi-omics is the 
interpretation of the results, which could benefit from borrowing and applying some of the 
principles of systems biology. The holistic characterization of a biological network produces a 
non-linear coherent network from individual multifunctional elements (Hillmer, 2015; Kitano, 
2002). Availability of data at multiple levels allows one to look at all the observable entities 
and their relationships to generate even new relationships and decipher system-level 
properties such as at organelle, cell, tissue, or organism level. Multi-omics system biology 
involves discovery, i.e., acquisition of data, analysis, and validation at a single omic level; 
representation, i.e., integration and visualization in a network; and application, i.e., how these 
data-driven networks help in clinical investigations (Eckhardt et al., 2020). 
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1.5.1. Network biology: 
 
Integration and interpretation of multi-omics data lead to a better understanding of the 
molecular components acting in a system. The brain, being a highly intricate and complex 
structure, has a dynamic and diverse proteome and these proteins interact with each other 
to create a stable or transitory protein complex. Moreover, proteins such as transcription 
factors, RNA binding proteins, among others, interact with RNA and form another layer of 
regulation, leading to multiple signaling cascades. To unravel these entwined processes and 
signaling pathways, approaches that can provide a system-wide view of the signaling network 
are required. These approaches can take the expression profiles of genes and proteins 
involved in a biological system and the protein-protein interaction knowledge from the 
literature and put the phenotype in relationship with the data.   
 
Inhibition of single drivers in multi-level signaling cascades can lead to compensatory 
mechanisms through alternative pathways. For example, a disease such as DS, which leads to 
genome-wide dysregulation at both RNA and protein levels, requires targeting not just the 
single drivers but multiple of them and, more specifically, the pathways itself, which could 
lead to higher efficacy of developed drugs. In this context, the molecular networks generated 
with data from different technologies may serve as a framework for better biological 
inferences. Indeed, these biological networks are an intermediate step for studying the 
genotype to phenotype relationships. 
 
Inside the cell, these molecular interactions often are organized into groups of proteins 
associated with a similar biological function and form modules (of proteins expression at 
similar levels) within a vast network (Becker et al.; Costanzo et al., 2010; Furlong, 2013; Ideker 
and Sharan, 2008; Taylor and Wrana, 2012). The phenomenon of modules is not confined to 
proteins but is also present for genes, as shown by Goh et al. (Goh et al., 2007). Within an 
interactome of all the proteins, functional modules are associated with the principle of "guilt 
by association", where the genes or proteins of similar expression will cluster together to form 
co-expressed gene clusters. This subnetwork of genes/proteins helps identify the hub 
molecules within a network and predict functions and novel disease-associated genes (Ideker 
and Sharan, 2008; Lee et al., 2011). These subnetworks could also help in pointing out never-
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before highlighted processes that are disrupted in the disease. Co-expression network 
analysis is suitable for interpreting and identifying distinct gene regulation levels and across 
different biological scales from cells to tissue (Hawrylycz et al., 2012; Miller et al., 2014; 
Oldham et al., 2008; Parikshak et al., 2013). 
 
1.5.2. Cell types from single-cell to bulk RNA-seq: 
 
The cell diversity inside the CNS has been traditionally studied by looking at their 
morphological and physiological features such as shape, immunohistochemical markers, 
electrical activity, and the cells' location (Bota and Swanson, 2007; Fishell and Heintz, 2013; 
Masland, 2004). Transcriptomic studies are required in fact to ascertain the molecular 
phenotypes of CNS cell types. Nevertheless, most gene-expression studies have analyzed the 
bulk tissue samples, which reflect an average of what is present in the single-cell types. 
Ideally, the solution to this problem is to isolate pure populations of single-cell types, which 
requires fresh extraction of tissue for good quality of expression profile. This is again limited 
to the model organism, and to take this approach to humans, would require resection of 
tissue during neurosurgeries. Few efforts have been undertaken along these lines in a limited 
number of regions, but those are timely, costly, and technically very challenging (Darmanis et 
al., 2015). 
 
Nevertheless, high-throughput single-cell RNA-seq (scRNA-seq) has started to provide a more 
comprehensive understanding of the transcriptional programs in an individual cell and 
identify novel cell types (Macosko et al., 2015; Tasic et al., 2018; Usoskin et al., 2015; Zeisel 
et al., 2015). Compared to model organism's scRNA-seq studies, where it has been much 
easier to isolate and sequence the cells, adult human CNS suffers from low throughput and 
contamination from other cells (Okaty et al., 2011). The approach to isolate single-nuclei from 
post mortem brains holds excellent promise but currently is limited in scope (Krishnaswami 
et al., 2016; Lake et al., 2016) 
 
Nevertheless, computation tools exist to obtain cell-specific expression profiles from bulk 
RNA sequencing by utilizing co-expression of genes. This concept is based on the assumption 
that different cells from heterogeneous tissues such as the brain express different genes. Thus 
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in bulk RNA-seq experiments, the genes which are consistently expressed explicitly across the 
samples will be inferred as a set of marker genes for that particular cell type. This gene 
expression profile for each cell type helps in deconvoluting the brain RNA-seq expression into 
individual cell types based on expression levels of genes.  
 
1.6. Alternative splicing in the mammalian brain: 
 
1.6.1. Alternative splicing: 
 
The genetic information is encoded in the DNA, which transcribes to RNA and then translates 
to protein to partake in various biological functions (CRICK, 1970). However, different cells in 
different areas of our body have distinct molecular signatures and perform diverse functions 
even if they carry identical DNA. This diversity is established with post-transcriptional 
regulation (Franks et al., 2017; Manning and Cooper, 2017). Post-transcriptional regulation 
consists of alternative splicing, poly(A) tailing, capping, RNA editing, miRNA regulation, 
transportation, mRNA modifications, and degradation (Bludau and Aebersold, 2020).  
 
Alternative splicing (AS) is the most ubiquitous and crucial phenomenon in generating diverse 
isoforms from a single gene. During AS of precursor mRNA, combinations of different 5' and 
3' splice sites, inclusion or exclusion of specific exons, or intron retention result in many 
isoforms. These different isoforms get translated to different protein products, which carry 
out different biological functions. More than 95% of human genes undergo alternative 
splicing and generate enormous diversity and complexity at the RNA level (Pan et al., 2008; 
Wang et al., 2008). Across all the tissues, the human brain undergoes the highest AS (Raj and 
Blencowe, 2015; Yeo et al., 2004). This generates isoforms that affect many aspects of 
neuronal development and function (Raj and Blencowe, 2015; Zheng and Black, 2013). The 
number of identified and novel AS events is context-specific, i.e., they are cell-type, tissue-
type, and development stage-specific (Calarco et al., 2011; Kalsotra and Cooper, 2011).  
 
Although alternative splicing has progressed a lot from identifying single splicing events to 
discover global networks, the functional consequences of these events have not been fully 
understood at the physiological or disease level. Improving the molecular information 
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regarding splicing networks in physiological conditions would help us understand better the 
dysregulation in various disorders. This advanced molecular understanding is currently 
possible thanks to deep RNA sequencing in a cell or tissue of interest in an unbiased manner. 
(Baralle and Giudice, 2017; Dillman et al., 2013). 
 
Pre-mRNA consists of both introns and exons, and during the splicing process, introns are 
spliced out, and exons are ligated together to form mature RNA. There are particular sites or 
sequences at intronic ends that define where the cleavage or ligation will occur. 5' splice site 
is at 5' end of the intron, and similarly, 3' splice site is at 3' end of the intron. The spliceosome 
machinery is responsible for splicing mechanisms. There, many factors come together at 
splice sites to perform the first cleavage and then ligation steps. The most common splicing 
event is exon skipping or cassette exon, where one exon is either included or excluded in the 
final mRNA product (Vuong et al., 2016) (Figure 1.2). Mutually exclusive exons are patterns 
where only one of the exons from a consecutive exon is kept in the mRNA. Alternative 5' and 
3' splice sites are donor and acceptor sites that change the length of exon at 3' end and 5' 
end, respectively. Alternative first exons (promotor) and last exons (poly(A) tail) create 
different first and last exons, respectively. Intron retention is a splicing event where the intron 
is retained or excised from the final mRNA. Lastly, microexon are 3-27 nt exons, skipped or 





Figure 1.2. Patterns of alternative splicing and the action of spliceosome components. Dark blue boxes 
represent constitutively expressed exons, and red and light blue boxes represent exons that undergo different 
kinds of alternative splicing events. (Park et al., 2018). 
 
 
1.6.2. Regulation of alternative splicing: RNA binding proteins 
 
The outcome of alternative splicing is influenced by the content of consensus sequences at 
the splice sites. Those are bound by the spliceosome machinery components, cis-regulatory 
sequences, and the expression levels of trans-acting factors such as RNA binding proteins 
(RBPs) and other splicing factors.  
 
RBPs constitute a large portion of trans-acting factors. They interact with RNA to control its 
synthesis and life cycle. Around 1500 proteins have been categorized as RBPs (Gerstberger et 
al., 2014), and their number continues to grow with the advent of large high throughput 
technologies. RBPs can shuttle between the nucleus and cytoplasm, affecting the biosynthesis 




Recently, a splicing code has been deciphered (Barash et al., 2010). Thus we are now able to 
predict splicing in different cells or tissues. The code mainly suggests that different RBPs could 
bind to the same regulatory sequences on the same or different transcripts; the same RBP 
could positively or negatively impact the binding motif's location, and RBPs could regulate 
each other (Figure 1.3). Nevertheless, information regarding the functional consequence of 
alternative splicing is still missing. However, studies by crosslinking and immunoprecipitation 
followed by sequencing (CLIP-seq), RNA immunoprecipitation followed by sequencing (RIP-
seq), and transgenic models where the RBP of interest is depleted or overexpressed in specific 
tissues are providing first information. Overall, we now know that multiple RBPs can regulate 
alternative splicing cooperatively and competitively.  
 
Figure 1.3. RNA binding proteins regulate multiple exons. Splicing regulators control large target exon sets that 
often overlap with those regulated by other RNA-binding proteins (RBPs) (Vuong et al., 2016).  
 
1.6.3. RBPs and splicing in the brain: 
 
Alternative splicing can impact multiple aspects of the nervous system, such as neuronal 
development, differentiation, and synaptic transmission (Raj and Blencowe, 2015; Vuong et 
al., 2016). Diverse RBPs regulate splicing in the brain. For example, expression levels of PTBP1, 
PTBP2, and SRRM4 play essential roles during neurogenesis. In neuronal progenitors, PTBP1 
induces the exclusion of exon 10 of PTBP2, which leads to exon 10 skipping and a transcript 
with premature termination codon. When progenitors differentiate to neurons, PTBP1 is 
downregulated, and a positive regulator of PTBP2 splicing, SRRM4, is upregulated. Hence, 
exon skipping is repressed, leading to the expression of PTBP2 promoting neuronal 




PTBP2 null mice die shortly after birth, and genes involved in the cytoskeleton and cell 
proliferation exhibit defects in alternative splicing. This misregulation of AS is also observed 
in genes regulating neurite outgrowth and synaptic transmission (Li et al., 2014b; Licatalosi et 
al., 2012).  
 
 
Figure 1.4. Changes in expression of PTBP1 and PTBP2 during neuronal differentiation (Li et al., 2014b). 
 
Another RBP family plays an essential role during neurodevelopment. The RBFOX family 
consists of three paralogs: RBFOX1, 2 & 3. Deleting RBFOX1 results in increased excitability of 
neurons in the dentate gyrus and susceptibility to seizures (Gehman et al., 2011) (Figure 1.5).  
RBFOX1 has also been implicated in neuronal differentiation (Fogel et al., 2012). Notably, 
RBFOX1 regulates its own alternative splicing for exon 19, resulting in two isoforms. One is 
nuclear (exon 19 excluded), and the other one is cytoplasmic (exon 19 included). RBFOX2 
deletion leads to improper migration, dendritic arborization of Purkinje cells, and increased 





Figure 1.5. Exon 19 (e.19) in RBFOX1 is alternatively spliced, giving rise to nuclear (lacking e.19) and 
cytoplasmic (containing e.19) protein isoforms. In RBFOX-depleted neurons, the misregulation of splicing 
networks controlled by RBFOX1 leads to defects in the expression of transcription factors, other splicing factors, 
and synaptic proteins. The introduction of exogenous nuclear RBFOX1 rescues changes resulting from the 
misregulation of splicing networks. The introduction of exogenous cytoplasmic RBFOX1 stabilizes multiple 
mRNAs (for example, by interfering with the binding of some microRNAs (miRNAs)), particularly the mRNAs of 
synaptic and autism-related genes. This stabilization increases the targeted genes’ protein expression, rescuing 
certain neuronal functions (Baralle and Giudice, 2017). 
 
Splicing regulatory networks within functionally related genes consist of co-regulated exons. 
NOVA 1 and 2 were the first RBPs found to perform this type of regulation. NOVA1 knockout 
results in motor failure and postnatal death, while NOVA2 null mice exhibit dysregulation of 
activity-dependent LTP of slow inhibitory postsynaptic current (Raj and Blencowe, 2015). 
Moreover, NOVA2 regulates neuronal migration, and possibly, it does so by splicing Dab1, a 
component of the reelin signaling pathway, which controls neuronal migration and cortical 
lamination. NOVA2 acts by repressing exon 7b and 7c of Dab1. This results in a product that 
undergoes ubiquitylation upon Reelin activation (Rice et al., 1998; Yano et al., 2010).  
 
1.6.4. Defects in AS results in neurological disorders:  
 
During neurodevelopment, the gene expression has to be tightly regulated, and AS is one 
crucial step in this regulation (Vuong et al., 2016). As neurons mature, they undergo dramatic 
and sophisticated changes in their morphology, such as the formation of synapses to build an 
intricate circuit. These processes are finely tuned by AS.  These exact and subtle changes occur 
through tuning of gene expression.  
 
Accordingly, abnormalities in AS have been associated with various neurodevelopmental 
disorders, including autism spectrum disorder (ASD) (Parikshak et al., 2016; Quesnel-Vallières 
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et al., 2019). For example, microexons are frequently misregulated in ASD and correlate well 
with reduced levels of SRRM4 (Irimia et al., 2014). Loss of SRRM4 leads to disruption in neurite 
growth, axon guidance, and neuronal migration in the forebrain (Raj et al., 2011). 
Interestingly, RBFOX splicing network is also misregulated in ASD individuals (Weyn-
Vanhentenryck et al., 2014).  
 
Moreover, DSCR1 gene from chromosome 21 (triplicated in Down syndrome) has alternative 
first exons as detected by rapid amplification of cDNA ends (RACE) technique (which provides 
the full length of RNA transcript). Interestingly cDNA library screening in Down syndrome has 
shown that all the exons of the DSCR1 gene are flanked by consensus sequence for RBPs 
(Fuentes et al., 1997). However, the functional consequence of these alternative exons has 
not been established. In DS fetal brains and Dyrk1a overexpression mouse models, a modest 
amount of splicing associated transcripts are modified due to change in location of 
spliceosome machinery components, which results in exon inclusion in few essential synaptic 
genes (Toiber et al., 2010). In an RNA-seq analysis from endothelial progenitor cells 
originating from one DS individual and one age and sex-matched control, the authors showed 
large-scale evidence of DS- specific alternative splicing (Costa et al., 2011).  Global changes in 
alternative splicing have also been reported in individuals with schizophrenia. In an RNA-seq 
study, more than 1000 genes showed differential splicing compared to the superior temporal 
gyrus of control individuals (Wu et al., 2012). Interestingly in another study on the 
dorsolateral prefrontal cortex (DLPFC), 798 differentially expressed transcripts were 
identified from 316 genes involved in the inflammatory response (Fillman et al., 2013). 
 
Finally, AS has also been implicated in neuropsychiatric disorders and neurodegenerative 
diseases such as Parkinson’s (Trabzuni et al., 2012), Alzheimer’s (Raj et al., 2018; Rockenstein 
et al., 1995), Amyotrophic lateral sclerosis (ALS) (Ling et al., 2015), and bipolar disorder (BP), 
for example, in BP, several risk genes have been associated with splice variants. One of the 
prominent genes with risk variants is ankyrin-G (Ank3), which has been identified in several 




Although there is a clear association of AS to brain disorders, to what extent the dysregulation 
of these neuronal exons and splicing networks contributes to various neurological disorders 
remains an important open question.  
 
1.6.5. Alternative splicing in axon formation: 
 
Neurons consist of a single axonal protrusion responsible for conducting action potential from 
the cell body to other cells. During axonogenesis, neurons first produce multiple, 
indistinguishable neurites. As the neuron matures, one of the neurites undergoes molecular 
and morphological changes to become the axon (Cheng and Poo, 2012) and grows into the 
final targeting area with the help of axon guidance molecules (Figure 1.6).  
 
 
Figure 1.6. Stages of axon formation (Zheng, 2020). 
 
Axon specification is established through morphological and molecular hallmarks of axons  
(Cáceres et al., 2012). For example, the axon is demarcated by Tau1 at the distal part and 
depletion of MAP2. After demarcation, microtubule polarity and axon initial segment 
acquisition occur, leading to axonal maturation (Szu-Yu Ho and Rasband, 2011). Finally, the 
axon forms branches and gets localized to the final destination. Notably, some of these axonal 
branches are pruned away during development, following an activity-dependent matching 
process (Zheng, 2020). Despite numerous studies on molecular players involved in 
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axonogenesis, we still do not fully understand the regulatory mechanisms that control the 
formation of a single axon, and thus the maintenance of neuronal polarity (Zheng, 2020). 
 
One of the possible mechanisms could be alternative splicing. This level of regulation has been 
recently studied in more detail through an unbiased transcriptome profiling of neurons 
before and after the initial axon formation (Zhang et al., 2019). The authors found many genes 
to undergo isoform expression changes during this period and exhibit neural-specific splicing 
patterns. Many genes did not change their gene expression when the neurons were growing 
out axons but underwent splicing (Zhang et al., 2019). 
 
For example, Shootin1 (SHTN1) changes from the long to the short isoform during axon 
formation, and excessive short isoforms lead to multiple axons (Kubo et al., 2015). Indeed, 
the short isoform (SHTN1S) is located at the axonal tip when an axon protrudes from the 
neuron. The SHTN1L shifts to SHTN1S form gradually, suggesting axonal growth precedes 
axon specification. This is because the gain and loss of function analysis for SHTN1S have 
shown that it is not responsible for promoting axonal growth, but SHTN1L is the one playing 
that role. This was supported by a previous study from Goslin and Banker in 1989, showing 
that axons and dendrites can switch fates even after initial axon outgrowth (Goslin and 
Banker, 1989). The authors performed axotomy experiments in rat hippocampal cultures. 
They reasoned that when the axon is 100-200 µm long, they can still become either axon or 
dendrite depending on each neurite’s rate of growth. 
 
Furthermore, Zhang et al. found out that RNA binding protein PTBP2 is a master regulator of 
axonogenesis-associated splicing. A significant number of axonogenesis-associated genes are 
affected by PTBP2 gain and loss (Zhang et al., 2019). Interestingly, the expression of PTBP2 
peaks during early axonogenesis in the brain (Zheng, 2016; Zheng et al., 2012) and Ptbp2 -/- 
axons are shorter, and 25% of neurons can generate two or more axons. Notably, the splicing 
of SHTN1 is regulated by PTBP2, and the long isoform is decreased, and the short isoform is 
increased in Ptbp2 -/- neurons (Figure 1.7). Thus, alternative splicing can regulate different 





Figure 1.7.  Alternative splicing regulation of early axonogenesis. (a) A neuron-specific alternative splicing 
program coordinates early axonogenesis (axonal growth and specification). A combinatorial and coordinated 
alternative splicing regulatory network encompassing many RBPs and alternative splicing events accompanies 
the morphological and molecular changes of axon formation. Alternative splicing of Shtn1 produces two 
isoforms. SHTN1L promotes axonal growth. SHNT1S promotes axon specification. FS indicates axon fate 
specification. (b) The axonogenesis-associated splicing program, including Shtn1, is coordinated by PTBP2. 
PTBP2 loss decreases SHTN1L and reduces axonal elongation. Meanwhile, SHTN1S is increased, and some Ptbp2-
/- neurons can extend two TAU1+ axons (Zheng, 2020). 
 
1.7. Role of miRNA regulation in the mammalian brain: 
 
1.7.1. miRNAs biology: 
 
miRNAs are 21-22 nucleotides in length, non-coding RNAs, and regulate gene expression 
(Bartel, 2004). They mainly interact with 3’ untranslated regions (UTR) of their target genes 
through their interaction with seed sequences of 6-8 nucleotides (nt) at their 5’ end (Lewis et 
al., 2005). Some miRNAs often belong to miRNA families where the members share identical 
seed sequences and perform similar physiological functions. For example, the let-7 family (let-
7a/7b) promotes neuronal differentiation (Bian et al., 2013). miRNAs are transcribed from 
intra- and inter-genic regions of the genome by RNA polymerase II. The primary miRNAs (pri-
miRNAs) consists of an imperfectly paired stem of about 33 nt, with a terminal loop and two 
flanking segments. After the pri-miRNAs are processed to precursor miRNAs (pre-miRNAs) 
and then to mature miRNAs, they are incorporated in the RNA-induced silencing complex 





In particular, the pri-miRNA is first processed by RBPs DGCR8 and Drosha in the nucleus. Those 
remove the stem-loop to form pre-miRNA. This pre-miRNA is then exported to the cytoplasm 
with exportin 5 and another RNase III enzyme, RBP Dicer. This processes the pre-miRNA to 
remove the terminal loop to finally form mature miRNA duplexes. The duplexes associate 
with the RBP Argonaute (Ago) proteins in the RISC, where one strand of the duplex is 
degraded, and another one is retained (Sharp, 2009) (Figure 1.8). Every step of miRNA 
biogenesis is tightly regulated, and any dysregulation has been associated with a variety of 
developmental defects and diseases (Rajman and Schratt, 2017).  
 
 
Figure 1.8. Biogenesis of miRNA in animals (Ha and Kim, 2014). 
 
The accurate prediction of miRNA targeting is essential for miRNA function in physiology and 
pathology. Three types of target sites have been described in terms of conservation and 
efficacy: 8mer, 7mer-m8, and 7mer-A1 sites (Figure 1.9). More than 60% of human protein-
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coding genes are targeted by one or more miRNA, and each miRNA could target multiple 
mRNAs. Similarly, each mRNA could be targeted by multiple miRNAs resulting in a complex 
regulatory network (Bartel, 2009). 
 
 
Figure 1.9. microRNA target sites. These sites each have 6-7 contiguous Watson-Crick pairs (vertical lines) to the 
miRNA's seed region (miRNA positions 2-8). Two of these sites also include an A at position 1. Relative site 
efficacy in mammalian cells is graphed to the right (log scale). The most effective sites are 7-8 nt sites that include 
a perfect match to the miRNA seed (positions 2-7, red), whereas the 6 nt sites are the least effective (Bartel, 
2018). 
 
1.7.2. RNA binding proteins and microRNAs: 
 
Whereas RBPs such as DGCR8 and Drosha are very well characterized in the processing of pri-
miRNAs, other RBPs in miRNA biogenesis has not been completely defined. Few RBPs that 
play specifically targeted roles include DKC1, which promotes excision of snoRNA-derived 
miRNAs from snoRNA host genes (Scott et al., 2009), and LIN28A, which inhibits the 
differentiation-inducing let-7 family expression in stem cells by interacting with pri-miRNA 
and pre-miRNA (Heo et al., 2009). RBPs can positively and negatively impact miRNA 
biogenesis and could affect different steps of the processing. This has led to identifying 116 
RBPs that could influence miRNA processing (Nussbacher and Yeo, 2018). For instance, 
hnRNPA1 stimulates microprocessor processing of miR-18a by changing the structure of pri-
miR-18a and make it more accessible to Drosha (Guil and Cáceres, 2007). On the other hand, 
hnRNPA1 negatively regulates let-7a-1 by binding to the conserved terminal loop (Michlewski 
and Cáceres, 2010).  Moreover, Nussbacher and Yeo have recently done a systematic analysis 
to identify RBP-pre-miRs interaction. RBPs can also regulate miRNA RISC loading. For instance, 
TDP43, a RBP associated with ALS, disrupts the loading of miR-1 and miR-206 in the RISC 
complex (King et al., 2014). These findings highlight that many RBPs could interact and 
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function in intermediary steps of miRNA processing, providing a broad layer of regulation of 
miRNA activity and abundance.  
 
1.7.3. miRNA in nervous system development: 
 
miRNAs represent an essential layer of post-transcriptional regulation, which fine-tunes 
expression profiles of genes necessary for neuronal development, maturation, and 
synaptogenesis. They have also been recognized as critical players in the formation and 
retrieval of memory and are associated with LTP and LTD (Hu and Li, 2017; Sambandan et al., 
2017). During synapse development, some miRNAs induce mRNA degradation, and others are 
involved in the regulation of mRNA translation (Schratt et al., 2006; Swanger and Bassell, 
2011). In polarized neurons, miRNA regulation can occur at the global level or specifically in 
axons or dendrites. These studies highlight the importance of miRNAs in the strict 
spatiotemporal regulation of gene expression, which is essential for neural circuit formation 
(Olde Loohuis et al., 2012; Wang et al., 2012; Ye et al., 2016). 
 
Several miRNAs are differentially expressed across developmental periods, and differential 
expression across regions increases over developmental time (Ziats and Rennert, 2014). 
Putative targets of these differentially expressed miRNAs are involved in biological processes 
such as neurodevelopment and transcriptional regulation. Some miRNAs are dynamically 
expressed during development resulting in some miRNAs being continuously expressed 
across all developmental phases (miR-9 and let-7), and few expressed for a short time. This 
suggests that the latter group of miRNA might be involved in time-specific processes during 
development, such as proliferation, migration, and network formation (Barca-Mayo and De 
Pietri Tonelli, 2014). In particular, miRNAs can regulate neurite/synapse formation and 
function. For example, BDNF is downregulated by miR-375 to inhibit dendritic growth 
(Abdelmohsen et al., 2010), miR-138 regulates the palmitoylation of several proteins 
functioning at synapses (Siegel et al., 2009), and miR-124 enhances long-term facilitation by 




Materials and methods 
2.1. Human samples RNA sequencing:  
 
2.1.1. Sample preparation:  
 
Human brain tissues for DS and control individuals were obtained from NIH NeuroBioBank. 
Brain sample and donor information are available in Table 1 and 2 in the appendix. No 
statistical tests were done before the acquisition of samples. A piece of the human 
hippocampus and cortex from both DS and control individuals were cryo-pulverized with the 
help of pestle and mortar. The crushed tissue was collected in a 1.5 ml eppendorf tube. About 
50 mg of crushed tissue was collected in another 1.5 ml Eppendorf and kept on dry ice until 
use. Briefly, RNA was extracted with QIAzol reagent and purified on miRNeasy spin columns 
(QIAGEN). RNA samples were quantified at 260 nm with an ND1000 Nanodrop 
spectrophotometer (Thermo Scientific). RNA purity was also determined by absorbance at 
280 and 230 nm. All samples showed A260/280 and A260/230 ratios greater than 1.9. RNA 
quality and integrity were verified by microfluidic assay with Agilent 2100 Bioanalyzer. The 
RNA integrity number (RIN) ranged between 2.1 and 7.3. 
 
2.1.2. Library preparation for whole transcriptome sequencing: 
 
500 ng RNA was used to prepare sample libraries. Briefly, Illumina’s TruSeq stranded total 
RNA library preparation kit was used. First, ribosomal RNA (rRNA) was depleted using Ribo-
Zero rRNA removal beads. Then the RNA is fragmented, and the first-strand cDNA synthesis 
is initiated. Following this, second-strand cDNA is synthesized, and 3' ends are adenylated. It 
is followed by adapter ligation to the cDNA strands, amplification, and purification of DNA 
fragments. All the sample libraries are then quantitated on Agilent 2100 Bioanalyzer. The size 
in bp and concentration (ng/µl) of the peak corresponding to the amplified products are taken 
for normalizing the libraries. The normalized libraries were then pooled together in a process 
called multiplexing (Figure 2.1). The pooled libraries were then loaded onto the Illumina S2 
flow cell. Paired-end sequencing for 100 bp each was performed on NovaSeq 6000 system to 
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obtain around 100 million reads per sample. The basecall files were then converted to fastq 
files and are demultiplexed to obtain each sample for further analysis.   
 
 
Figure 2.1. Workflow for preparing total RNA sequencing libraries. 
 
2.1.3. RNA-seq read alignment and quality check: 
First, all the raw reads were run through FastQC v0.11.9 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). FastQC output was 
compiled by use of multiQC and visually inspected to look for “sequence quality”, “per tile 
sequencing quality”, “overrepresented sequences” , “adapter content” and other quality 
parameters. All the samples with good quality parameters were carried forward for the 
alignment. Fastq files were aligned with STAR v2.7.3a (Dobin et al., 2013) to Homo sapiens 
GRCh38 genome, Ensembl version 99 (Yates et al., 2020). The fastq files were mapped using 
2pass mapping parameters. In the first pass mapping, each file was mapped to the reference 
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genome with 1pass mapping parameters. Then, the mapped spliced junctions for each sample 
were extracted and concatenated. The junctions originating from mitochondrial genes were 
filtered out. A new index was created based on the concatenated splice junctions, and then 
the 2pass mapping was performed on the 1pass mapped files. The output of the 2pass 
mapping consisted of bam files and reads per gene information for each sample. These were 
the raw counts to be used for further analysis. The bam files were also checked for quality 
controls using PicardTools v2.23.6 (http://broadinstitute.github.io/picard). The number of 
reads obtained for each sample is available in Table 3 in the appendix. 
2.1.4. Differential gene expression: 
The raw counts from STAR were imported in RStudio (RStudio Team (2020)) for performing 
differential expression analysis. Differential expression analysis was performed using edgeR 
v3.32.1, a statistical package based on generalized linear models. The normalization was 
performed using the Trimmed means of M values (TMM) method (Robinson et al., 2010). The 
differential expression analysis was performed for those genes which were present in at least 
“n-1” samples for the group with less number of samples. The counts for filtered genes were 
subsequently used to calculate log2 fold changes for DS vs. control samples, and the significant 
genes were taken to be those with a false discovery rate (FDR) of <0.05. 
2.1.5. Expression profile visualization: 
 
The differentially expressed genes were visualized onto different chromosomes with the help 
of rtracklayer (Lawrence et al., 2009) and ggbio (Yin et al., 2012) R packages. Further, the gene 
expression profile for all the genes was visualized using karyoploteR (Gel and Serra, 2017) and 
regionR (Gel et al., 2016) R packages to obtain genome-wide dysregulation domains (GEDDs). 
The identification of GEDDs for each chromosome was validated by performing loess 
regression with 3% smoothing and 1000 bootstrap tests. The genes located in the GEDDs and 
their log2 fold changes and start location were extracted into a table for each chromosome 
separately.  The default parameters from the original study were used to calculate the start 
and end of each GEDD (Letourneau et al., 2014). The number of GEDDs for each chromosome 




2.1.6. Identifying biological pathways: 
 
clusterProfiler (Yu et al., 2012) R package was used to perform Gene Set Enrichment Analysis 
(GSEA) (Subramanian et al., 2005) on the Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathways (Kanehisa et al., 2016). The gene expression profile for each brain region was tested 
against the KEGG pathways database with 10000 permutations, and p-value cutoff <0.05, and 
the enrichment was plotted using the ridgeplot function. Pathway maps for enriched 
pathways were plotted using pathview (Luo and Brouwer, 2013) R package with human 
pathway IDs.  
 
2.2. Gene Ontology analysis: 
 
GO enrichment analysis was performed using The Database for Annotation, Visualization, and 
Integrated Discovery (DAVID) (Huang et al., 2009) with a high level of stringency among three 
different levels (medium, high and highest). The GO analysis was performed for biological 
processes (BP), cellular components (CC), and molecular functions (MF), and the results were 
multiple-testing corrected with the Benjamini-Hochberg test (Benjamini and Hochberg, 
1995). Heatmaps were created using the ComplexHeatmap R package (Gu et al., 2016). 
 
2.3. Cell-type enrichment analysis: 
We integrated the Zeisel et al. (Zeisel et al., 2015) data with cell-type-specific transcriptome 
signatures from mouse cortex and hippocampus with the bulk RNA-sequencing data for the 
human hippocampus and cortex that we generated. The Expression Weighted Cell-type 
Enrichment (EWCE) R package (Skene and Grant, 2016) was used to obtain this integration. 
Two ranked gene lists, one for significantly upregulated genes for both the regions and 
another for significantly downregulated genes for both regions separately, were ordered 
according to their Log2 Fold Change (FC). In EWCE, random samples were obtained by 
reordering the ranked list 100,000 times. Transcript length and GC content were controlled 
during the analysis. Data were represented as Z-scores, i.e., standard deviations from the 
mean. Values below 0 indicate depletion in expression, which has been assigned the value of 
0. Heatmaps were created using superheat R package (Barter and Yu, 2018). 
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2.4. Weighted Gene / Protein Co-expression Network Analysis: 
 
R package WGCNA (Langfelder and Horvath, 2008) was to construct co-expression networks, 
as previously done (Oldham et al., 2008). Briefly, the soft power parameter is chosen between 
6 and 9 for the signed hybrid networks when the network achieves scale-free topology 
(R2>=0.9) and a negative slope. Networks were constructed using the 'blockwiseModules’ 
function. Then the topological overlap matrices (TOM) are constructed and clustered 
hierarchically using average linkage hierarchical clustering using “1-TOM” as dissimilarity 
measure (dissTOM). TOM reflects how close the neighbors of a gene are to neighbors of 
another gene, i.e., network interconnectedness. Modules were defined as branches of 
dendrogram using hybrid dynamic tree cutting method with biweight midcorrelation (bicor), 
with a minimum module size of 30, deepsplit of 2. The modules generated initially were 
merged based on module eigengenes using correlation-based adjacency as dissimilarity 
matrix. Modules with a distance of <0.25 were merged into a single module. 
 
Each module was summarized by module eigengene (ME), which reflected the characteristic 
expression profile of a module. For each gene, the module membership measure (kME) was 
defined as the correlation between gene expression values and the module eigengene (ME). 
To assess the statistical significance of module membership, a Bonferroni corrected p-value 
was also calculated. Further derivation of intramodular connectivity measures helped identify 
the key players in the network, which were the hub genes. Module-Trait associations are 
computed with biological (Group: DS or control, Sex: Female or male, Age in years) and 
technical traits such as postmortem interval (PMI) in hours. Modules were considered to be 
significant with any trait if the Bonferroni corrected p-value <0.05. The Cytoscape edges and 
nodes parameters were obtained from modules with significant module-trait association with 
group trait. These nodes and edge parameters for significant modules were imported in 
Cytoscape (Shannon et al., 2003). The genes present in each module were used for creating 
interaction networks, cell-type enrichment, and gene ontology analysis. Correlation analysis 
was performed between the modules using the module membership values and Pearson's 




2.5. Human samples Quantitative PCR:  
Reverse transcription was performed according to the manufacturer’s recommendations on 
1 µg of RNA with the QuantiTect Reverse Transcription Kit (QIAGEN), including a genomic 
DNA–removal step. SYBR green qRT- PCR was performed in triplicate with 10 ng of template 
cDNA using QuantiTect Master Mix (QIAGEN) on a 7900-HT Fast Real-time System (Applied 
Biosystems) and using the following universal conditions: 5 min at 95oC, 40 cycles of 
denaturation at 95oC for 15 s, and annealing/extension at 60oC for 30 s. Product specificity 
and occurrence of primer dimers were verified by melting-curve analysis. Primers were 
designed with Beacon Designer software (Premier Biosoft) to avoid template secondary 
structure and significant cross-homology with other genes by BLAST search. For each target 
gene, primers were designed to target all possible transcript variants annotated in the RefSeq 
database (https://www.ncbi.nlm.nih.gov/refseq).  
In each experiment, no-template controls and RT-minus controls were run in parallel to the 
experimental samples. The PCR reaction efficiency for each primer pair was calculated via the 
standard curve method with four serial-dilution points for cDNA (32, 8, 2, and 0.5 ng). The 
PCR efficiency calculated for each primer set was used for subsequent analysis. All 
experimental samples were detected within the linear range of the assay. Gene-expression 
data were normalized via the multiple-internal-control-gene method (Vandesompele et al., 
2002). To determine an accurate normalization factor for data analysis, we evaluated the 
expression stability of different control genes with the GeNorm algorithm available in 
qBasePlus software (Biogazelle). The tested control genes were GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) and ACTB (actin B). Based on the relative expression stability of 
the control genes calculated via GeNorm analysis, expression data for the different samples 
were normalized with GAPDH and ACTB. The list of oligonucleotides with primer efficiencies 





2.6. Mass-Spectrometry Based Proteomics: 
 
2.6.1. Sample preparation: 
Samples of the human DS hippocampus and cortex and their age-/sex- matched healthy 
controls were lysed in Radio immunoprecipitation assay (RIPA) buffer. The prepared samples 
were loaded directly into the separation column, and the peptides were eluted. The peptide 
separations were carried out at 55°C by a 75-μm ID×50cm 2μm, 100 Å C18 column-mounted 
in the thermostatic column compartment of the machine. Eluting peptides were 
electrosprayed and analyzed by tandem mass spectrometry.  
2.6.2. Proteomic data analysis: 
The raw data were processed with MaxQuant software (Cox and Mann, 2008). A false 
discovery rate (FDR) of 0.01 was requested for the identification of proteins. Quantification 
in MaxQuant was performed using the built-in label-free quantification algorithm (Luber et 
al., 2010), enabling the “Match Between Runs” (Nagaraj et al., 2012). All proteins and 
peptides matching to the reversed database were filtered out. Label-free protein quantitation 
(LFQ) was performed with a minimum ratio count of 1 (Cox et al., 2014).  
2.6.3. Proteomic bioinformatic analysis: 
 
All bioinformatics analyses were performed with the Perseus software of the MaxQuant 
computational platform (Tyanova et al., 2016). Protein groups were filtered to require 100% 
valid values in at least one experimental group. The label-free intensities were expressed as 
base log2, and empty values were imputed with random numbers from a normal distribution 
for each column to best simulate low abundance values close to the noise level. A Student's 
t-test with permutation-based FDR statistics was run for each sample and 250 permutations 






2.7. Transcript quantitation: 
 
Transcripts for each sample were quantified using RSEM (Li and Dewey, 2011), and the 
differential expression for transcripts was performed with the EBSeq R package (Leng et al., 
2013). 
 
2.8. Alternative splicing detection: 
 
We performed alternative splicing detection using VAST-TOOLS and vastdb version 
hs2.23.06.20 (Tapial et al., 2017). First, each sample fastq file was aligned to the human 
vastdb database with default parameters. These aligned outputs were merged according to 
the group status (i.e., DS or control). The ‘vast-tools combine’ command was used to create 
a final output file. This output file was taken to calculate different splicing for five different 
kinds of alternative splicing events (ALTD, ATLA, EX, MIC, IR) using the 'tidy' module. The tidy 
module extracts inclusion levels (events) for each exon from all the genes with their percent 
spliced in values (PSI). Events were significant when average changes between the two groups 
with percent spliced in value |deltaPSI|>10 with sufficient read coverage in >80% samples 
from each group. For the intron retention events, percent intron retention (PIR) values are 
reported. 
 
2.9. RT-PCR validation of splicing quantification: 
 
1 µg of RNA for each sample was reversed transcribed by Qiagen QuantiTect RT kit in 20ul 
reaction. A control cDNA was PCR amplified for a different number of cycles (20, 25, 30, 35, 
and 40) to test for the number of cycles before the product reached saturation and resolved 
by electrophoresis on 2% agarose gel. After obtaining the desired number of cycles for each 
gene, all the control and DS human sample cDNAs were PCR amplified and run on agarose 
gels. Gels were quantified using ImageJ (NIH). The list of primers with sequences and number 




2.10. Agarose Gel Electrophoresis: 
 
All agarose gels for electrophoresis were prepared using 1X TBE supplemented with ethidium 
bromide. The 2% gels were run with 1X TBE running buffer for 40 minutes at 80V.  
 
2.11. Small RNA sequencing: 
 
2.11.1. Small RNA library preparation: 
 
500 ng RNA was used to prepare small RNA sequencing libraries with the help of NEXTFLEX 
Small RNA-seq kit v3 (PerkinElmer). This kit utilizes adapters with 4 nucleotides (4N) long 
randomized ends in order to reduce ligation bias. First, the RNA was denatured at 70oC, and 
the 3' 4N adapter was ligated. The excess adapter was removed, and then the 5' 4N adapter 
is ligated onto the sequences. This is followed by reverse transcription to generate cDNA and 
was purified using bead cleanup. The purified cDNA was PCR amplified with 18 cycles and 
barcoded primers. Then gel-free cleanup was performed to obtain the final libraries (Figure 
2.2). The libraries were quantified with Qubit, and quality checked on Agilent bioanalyzer. 
Like total RNA sequencing, the libraries were normalized and pooled to run on Illumina S1 




Figure 2.2. Workflow to prepare small RNA libraries 
 
2.11.2. Small RNA alignment, differential expression, and target prediction: 
 
Like total RNA sequencing, the basecalls files were converted to fastq files and checked for 
quality control using FastQC. The adapter sequences from fastq files for each sample were 
trimmed using Cutadapt v1.16 (Martin, 2011), followed by trimming 4 nucleotides from each 
end. The trimmed fastq files were mapped using miRge2.0 (Lu et al., 2018) onto the miRBase 
(Kozomara et al., 2019). Subsequently, the counts were obtained for each miRNA, and they 
were used to perform differential expression analysis with edgeR package.  
 
To look for targets of these differentially expressed miRNAs, conserved family predictions 
were downloaded from TargetScanHuman v7.2 (Agarwal et al., 2015). The targets for each 
differentially expressed miRNA were filtered out separately from the downloaded file. The 
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predicted targets were then annotated with log2FC and FDR from RNA-seq and proteomics 
experiments to find differentially expressed targets. 
 
2.12. Primary culture: 
The primary hippocampal culture was prepared from wildtype and Ts65Dn postnatal day 2 
pups as described. Brains were dissected under a stereomicroscope in ice-cold dissection 
buffer (Hank's Balanced Salt Solution (HBSS) with 6 mg/ml glucose, 3 mg/ml bovine serum 
albumin (BSA), 5.5 mM MgSO4, 5 ug/ml gentamycin, and 10 mM HEPES, pH 7.4). Hippocampal 
tissue was minced and enzymatically digested with 0.25% trypsin in HBSS consisting of 0.6 
mg/ml DNase for 5 mins at 37°C.  Tissue chunks were washed in DB, incubated for 5 min in 
DB supplemented with 1 mg/mL of Soybean trypsin inhibitor (Sigma), and mechanically 
dissociated in DB supplemented with 0.6 mg/mL DNase. Cells were passed through a 40 μm 
cell strainer and then centrifuged (110 x g for 7 min at 4°C) to remove cellular debris. Cells 
were plated on glass coverslips, 6-wells plates, or MEA coated with 0.1 mg/ml poly-L-lysine in 
100 mM borate buffer, pH 8.5 at a density of 250-500 cells/mm. Neurons were maintained in 
a culture medium consisting of Neurobasal-A supplemented with 2% B27, 1% GlutaMax and 
5 μg/mL gentamycin (all from Gibco) at 37 °C in humidified atmosphere (95% air, 5% CO2).  
2.13. Immunocytochemistry: 
 
The primary hippocampal culture was grown on sterilized, and poly-L-lysine coated coverslips. 
The cells were fixed at days in vitro (DIV14) with 4% paraformaldehyde in PBS for 20 minutes 
at room temperature. Fixed cells were washed 4 times 10 minutes each with PBS to wash 
away the PFA. The cells were then permeabilized with 0.1% Triton/PBS (PBST) for 3 times 10 
minutes each. This was followed by blocking with 5% normal goat serum (NGS) in PBST for 1 
hour and then primary antibody incubation overnight at 4oC. The coverslips were washed 4 
times 10 minutes each with PBST and followed by 2 hours incubation at room temperature 
with secondary antibodies. Coverslips were mounted on the glass slides with ProLong Gold 
with DAPI and imaged on Leica SP5 confocal microscope using 40X oil objectives. The cells 
were imaged using 0.5 µm z-steps, and the images were projected into a single plane using 
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maximum intensity projections. The list of antibodies used for immunocytochemistry is 
available in Table 7 in the appendix. 
 
2.14. Axon initial segment analysis: 
 
The maximum projected images were imported into MATLAB software (Mathworks) for AIS 
analysis using custom scripts as previously developed by Grubb’s lab (Grubb and Burrone, 
2010). The script determines the AIS length based on the AnkG intensity profile along a traced 
path. The AIS start and end is based on the intensity reaching 1/3 of the maximum intensity. 
For each genotype (wildtype and Ts65Dn), each neuron was analyzed to measure the AIS 
length. The neurons were also manually counted in ImageJ (NIH) containing no axons, single 
















3.1. Large gene-dysregulation in human hippocampus and cortex in DS vs. control  
individuals. 
 
To start our investigation on new molecular targets that could rescue cognitive impairment 
in DS, we first performed total RNA sequencing on 11 control and 9 DS hippocampal human 
samples. Among all the RNA biotype entities identified by the RNA sequencing, we found the 
majority of them were protein-coding genes followed by long non-coding RNAs (lncRNAs) and 
then pseudogenes and other RNAs such as unprocessed pseudogenes, miscellaneous RNAs 
(misc RNA), small nuclear RNAs (snRNAs), microRNA (miRNA), To be experimentally 
confirmed (TEC) RNAs, small nucleolar RNAs (snoRNAs), and others small RNAs (Figure 3.1). 
We restricted our analysis to the protein-coding genes. The expression levels of these genes 
were normalized according to the library size for each sample to obtain counts per million 
(CPM) reads. After acquiring the normalized counts for each gene within each specimen, we 
performed a quality control check by performing a Principal Component Analysis (PCA, which 
indicates variation in the data, i.e., how well individual samples from each group vary among 
themselves), a hierarchical clustering analysis (which assembles samples that are more similar 
to each other than the samples from another group) and sample RNA integrity number (RIN, 
which gives a measure of RNA integrity, i.e., is the RNA stable or degraded based on the ratio 
of 18S to 28S ribosomal subunits) on all data. So, we discarded samples based on a 
combination of these three criteria. In particular, we discarded outliers by PCA and 
hierarchical clustering analysis, and we excluded samples with degraded RNA. We eventually 
retained RNA-seq data from 6 controls and 6 DS individuals for the hippocampus. Similarly, 
cortical samples were checked and filtered from initial 12 control and 10 DS samples to retain 







Figure 3.1. Diverse RNA biotypes identified from total RNA-seq experiments. In the human samples, diverse 
RNA biotypes were identified and are shown with the help of a pie chart. lncRNA: long non-coding RNA, misc 
RNA: miscellaneous RNA, snRNA: small nuclear RNA, miRNA: microRNA, TEC: To be Experimentally Confirmed 
RNA, snoRNA: small nucleolar RNA. The numbers inside the pie chart shows the percentages of each biotype. 
 
To investigate gene expression changes in the DS hippocampus and cortex vs. control 
individuals at the level of a single gene, we carried out a differential expression analysis 
separately for both regions. We defined differentially expressed genes (DEGs) by a false 
discovery rate (FDR) of < 0.05 (Figure 3.2). Overall, we found 2622 up- and 2205 down-
regulated genes in the hippocampus and 2769 up- and 2779 down-regulated genes in the 
cortex (Figure 3.3A, 3.3B). Of the 180 triplicated genes present on the Chromosome 21, 
excluding the keratins associated proteins (KAPs), 63 and 88 genes were differentially 
expressed in DS vs. control samples in the hippocampus and cortex, respectively. All 
differentially expressed triplicated genes were upregulated (Figure 3.3C). 
 
 
Figure 3.2. Differentially expressed genes defined by FDR <5%. Schematic diagram to represent differentially 




We then compared DEGs from the hippocampus and cortex to determine whether there are 
region-specific changes in DS vs. control samples. We found that the number of up-regulated 
and downregulated genes in the hippocampus was less than in the cortex. Moreover, there 
were more up-regulated genes than down-regulated genes in the hippocampus, but almost 
an equal amount of genes were up-regulated and downregulated in the cortex. Notably, many 
differentially expressed genes were shared between the hippocampus and cortex (i.e., 1852 
up-regulated, 1654 downregulated, and 30 triplicated genes; Figure 3.3). Altogether, these 




Figure 3.3. Gene expression dysregulation in brain samples from individuals with DS. Venn diagram of 
differentially expressed genes in human hippocampus and cortex reveals common and non-common 






3.2. Differentially expressed genes belong to biologically significant processes and 
pathways.  
 
To understand the biological significance of these differentially expressed genes, we next 
performed a gene ontology (GO) analysis on the DEGs separately for the hippocampus and 
cortex. GO analysis is an unbiased enrichment analysis that reveals the representation of a 
set of genes in different biological processes (BP), cellular components (CC), and molecular 
functions (MF). In particular, we analyzed the upregulated and downregulated genes for each 
brain region individually. We found many processes shared between the two regions (Figure 
3.4). For example, biological processes such as cell death, collagen metabolic process, 
interferon-gamma mediated signaling, locomotion, phosphorylation, and cellular 
components such as extracellular vesicle and cell-substrate junction were shared by the 
upregulated genes in both regions. 
 
Similarly, many shared GO terms for downregulated genes include cell projection 
morphogenesis, macromolecular complex assembly, mRNA splicing, protein localization, 
translation, transport, and respiratory electron transport chain (Figure 3.5). On the other 
hand, we also found region-specific processes and functions. For example, for upregulated 
genes, we found cellular response to stimulus, ensheathment of neurons, neurogenesis, 
endoplasmic reticulum specific to the hippocampus, and terms like activation of immune 
response, hematopoiesis, histone deacetylation, mononuclear cell proliferation, MAPK 
cascade, and viral process specific to the cortex. For downregulated genes, axon 
development, RNA capping, and cellular biosynthetic process were hippocampus specific. 
Simultaneously, neurotransmitter secretion, synaptic signaling, proton transport, and 
regulation of mitotic spindle assembly were cortex specific biological processes. These DEGs 
provide a molecular signature for distinguishing between the DS and control brains with 








Figure 3.4. Differentially expressed upregulated genes show region-wise conserved and specific GO terms. 
Gene ontology (GO) analysis for upregulated genes for both hippocampus and cortex shows high levels of 
overlapping terms, but also specific ones. Purple dots represent hippocampus and pink dots represent cortex. 




Figure 3.5. Differentially expressed downregulated genes show region-wise conserved and specific GO terms. 
Gene ontology (GO) analysis for downregulated genes for both hippocampus and cortex shows some 
overlapping terms and few specific ones. Purple dots represent hippocampus and pink dots represent cortex. 
BP: Biological Processes, CC: Cellular Components, MF: Molecular Function, FDR: False Discovery Rate. 
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Many different studies have reported dysregulation in several biological pathways in DS 
(Cairney et al., 2009; Yu et al., 2020) and have found cell- and tissue-specific pathways to be 
disturbed. To look for dysregulated pathways in our datasets, we took advantage of the Kyoto 
Encyclopedia of Genes and Genomes (KEGG) pathways database originating from literature. 
The KEGG pathways database consists of manually curated pathway maps to find gene 
interactions and network relationships. To establish the enrichment of genes highlighted by 
our RNA seq analysis in KEGG pathways, we performed a Gene Set Enrichment Analysis 
(GSEA). It considers all the genes according to their Log2 fold change (FC) irrespective of their 
statistically significant differential expression status. In the hippocampus, we found that the 
genes with log2FC >0 were enriched in mostly immunological pathways such as complement 
and coagulation cascades, staphylococcus aureus infection, and antigen processing and 
presentation, cytokine-cytokine receptor interaction, and many more. On the other hand, the 
genes with log2FC <0 were enriched in ribosomal and proteasomal pathways (Figure 3.6). 
These results suggest immune dysregulation and protein synthesis, and degradation defects 
in the hippocampus. In figure 3.7, we showed two KEGG pathways as an example (i.e., 
complement and coagulation cascades; Figure 3.7A) where most of the genes were 
upregulated and another example (i.e., RNA transport; Figure 3.7B) where a majority of 
pathway components were downregulated. In the cortex, the genes with log2FC >0 were 
enriched in immunological pathways similarly to the hippocampus (Figure 3.8). On the other 
hand, the genes with log2FC <0 were enriched in neural pathways, mostly involving different 
kinds of synapses such as GABAergic, dopaminergic and glutamatergic synapses, and enriched 
in proteasomal and ribosomal pathways. They also showed enrichment in LTP, synaptic 
vesicle cycle, gap junction, circadian entrainment, and few neurodegenerative disorders 
(Figure 3.8). This result would suggest a dysregulation in neural-immune trajectory. As we did 
for the hippocampus examples, we similarly map the downregulated genes from the cortex 





Figure 3.6. Enrichment of immunological, ribosomal and proteasomal pathways in human DS hippocampus. 
GSEA analysis for all the protein-coding genes identified in the human hippocampus samples reveals KEGG 
pathways which were found to be enriched in immunological and ribosomal and proteasomal pathways. In red 
brackets are immunological pathways, in blue brackets are ribosomal and proteasomal pathways. The color bar 
on the left indicates FDR (obtained after Benjamini-Hochberg multiple testing correction). KEGG: Kyoto 




Figure 3.7. Examples of enriched KEGG pathways in human DS hippocampus. Mapping of log2FC values on the 
KEGG pathways from hippocampus reveals which genes from these pathways are differentially expressed. A) 
Complement and coagulation cascades pathway B) RNA transport pathway. Genes are color coded by their 
log2FC values where red indicates upregulated, green indicates downregulated, grey indicates no differential 
expression and white represent those genes not found in our data. Range of log2FC is shown by the color bar on 




Figure 3.8. Enrichment of immunological and neuronal pathways in human DS cortex. GSEA analysis for all the 
protein-coding genes identified in the human cortex samples shows KEGG pathways which were found to be 
enriched in immunological neural pathways. In red brackets are immunological pathways, in blue brackets are 
ribosomal, proteasomal and neural pathways. The color bar on the left indicates FDR (obtained after Benjamini-
Hochberg multiple testing correction). KEGG: Kyoto Encyclopedia of Genes and Genomes, FC: Fold change, FDR: 




Figure 3.9. Example of enriched KEGG pathway in human DS cortex. Mapping of log2FC values on the 
downregulated pathway synaptic vesicle cycle shows differentially expressed genes involved in the pathway. 
Genes are color-coded by their log2FC values where red indicates upregulated, green indicates downregulated, 
grey indicates not differentially expressed and white represent those genes not found in our data. Range of 
log2FC is shown by the color bar on top. FC: Fold change. 
 
3.3. Differentially expressed genes are divided into significant brain cell types. 
 
The human brain comprises multiple cell types (e.g., astrocytes, microglia, oligodendrocytes, 
interneurons, pyramidal neurons). The expression changes we observed at the bulk tissue 
level could result from the change in proportions or expression levels of these cells among 
the diverse experimental groups. We cannot calculate the proportion of different cells in a 
bulk RNA sequencing dataset, but it is possible to look for expression changes originating from 
different cells. To this aim, we took advantage of single-cell RNA sequencing (scRNA-seq) 
results on astrocytes, microglia, oligodendrocytes, interneurons, and pyramidal cells from 
mouse cortex and hippocampus available in the literature (Zeisel et al., 2015). We used a 
recently developed algorithm known as Expression Weighted Cell-type Enrichment (EWCE) 
analysis (Skene and Grant, 2016). The EWCE analysis tests for enrichment for a gene list of 
interest (in our case, the DEGs from the bulk RNA-seq data from hippocampus and cortex) 
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against the cell-type expression levels and computes whether the enrichment is statistically 
significant or it just occurs by chance. 
 
After performing cell-type enrichment analysis on the DEGs from hippocampus and cortex, 
we found that enrichment in different cells was consistently shared between the two regions 
with high significance (high z-scores, which denotes the number of standard deviations away 
from mean); Figure 3.10). In particular, both the hippocampal and the cortical upregulated 
genes showed clear enrichment in glial cells (astrocytes, microglia, and oligodendrocytes), 
whereas the downregulated genes showed clear enrichment in neural cells such as 
interneurons and pyramidal cells. Altogether our results indicated that there is an 
involvement of neural-immune dysregulation in Down syndrome. 
 
 
Figure 3.10. Differentially expressed genes show cell-type enrichment in human DS hippocampus and cortex. 
Upregulated genes in hippocampus and cortex show enrichment in glial cells and downregulated genes reveal 
neural cells enrichment. The numbers in the heatmap represent the z-score (number of standard deviations 
away from mean) for the significant enrichment (Bootstrap significance testing with 100,000 repetitions) and 
the color bar on right represent the level of fold enrichment. Dysregulation of gene expression in DS is present 
at genome-wide level. 
 
Since we found a high amount of dysregulation among the triplicated and non-triplicated 
genes and dysregulation in a wide variety of biological processes and pathways, we thought 
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to map the DEGs that we found in our bulk RNA-seq analysis based on their chromosome 
location. This analysis allowed us to identify which chromosomes showed the most 
dysregulation in DS (Figure 3.11). As expected, many upregulated genes were present on 
chromosome 21 because of the trisomy. Notably, there were other chromosomes, too, 
showing many dysregulated genes in both the hippocampus and the cortex (Figure 3.12). 
 
 
Figure 3.11. Differentially expressed genes show genome-wide dysregulation in human hippocampus.  
Differentially expressed genes are represented by their location in megabases (Mb) (x-axis) on different 
chromosomes, and shows upregulated genes in red and downregulated genes in blue. Numbers inside the plot 





Figure 3.12. Differentially expressed genes show genome-wide dysregulation in human cortex. Differentially 
expressed genes are represented by their location in megabases (Mb) (x-axis) on different chromosomes, and 
shows upregulated genes in red and downregulated genes in blue. Numbers inside the plot shows the number 
of up and downregulated genes, and black arrow represents chromosome 21. 
 
Next, we investigated whether the DEGs are organized in domains termed as gene-expression 
dysregulation domains (GEDDs) of upregulated and downregulated genes, as previously 
observed in fetal fibroblasts from DS individuals (Letourneau et al., 2014). The authors 
observed a consistent pattern across all the chromosomes for an alternating increase and 
decrease in gene expression (GEDDs) across large segments of chromosomes. To find GEDDs 
in our gene expression data from the bulk RNA-seq experiments from the hippocampus and 
the cortex, we performed loess smoothing on the gene expression for all the chromosomes.  
We found around 1356 and 1676 GEDDs in total for both the hippocampus and the cortex 
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respectively across all the chromosomes combined. Figure 3.13 shows two examples  (chr1 
and chr11) from hippocampus gene expression, where we found 148 and 77 GEDDs, 
respectively. 
 
Similarly, in the cortex, for example, on chr1 and 11 (Figure 3.14), we found 210 and 85 
GEDDs, respectively. In our analysis of adult human hippocampal and cortical samples, we 
similarly found GEDDs on all chromosomes. The size of the domains ranges from 0.2 kilobases 
(kb) to 42 megabases (Mb) (Figure 3.13). 
 
 
Figure 3.13. Identification of GEDDs in human DS hippocampus. Genome-wide Expression Dysregulation 
Domains (GEDDs) present on chromosome 1 and 11 are shown on hippocampus gene expression data. Each 
panel is divided into three subgraphs: the top graph represents GEDDs by the log2 fold changes (on y-axis) across 
the chromosome position (x-axis) with red dots showing upregulated genes, blue dots showing downregulated 
genes and grey dots non differentially expressed genes. This graph shows clear domains of upregulated and 
downregulated genes across the length of the chromosome. The gray shaded region represents the 95% 
confidence interval for the loess smoothing performed on the gene expression to define the domains. The 
middle graph shows the karyotype diagram of the respective chromosome and bottom graph represent the 
number of genes present on that specific chromosome region (gene density)  for all the genes normally present 





Figure 3.14. Identification of GEDDs in human DS cortex. Cortex gene expression data exhibits Genome-wide 
Expression Dysregulation Domains (GEDDs) present on chromosome 1 and 11. Each panel is divided into three 
subgraphs: the top graph represents GEDDs by the log2 fold changes (on y-axis) across the chromosome position 
(x-axis) with red dots showing upregulated genes, blue dots showing downregulated genes and grey dots non 
differentially expressed genes. This graph shows clear domains of upregulated and downregulated genes across 
the length of the chromosome. The gray shaded region represents the 95% confidence interval for the loess 
smoothing performed on the gene expression to define the domains. The middle graph shows the karyotype 
diagram of the respective chromosome and bottom graph represent the number of genes present on that 
specific chromosome region (gene density) for all the genes normally present on that chromosome, shown here 
to indicate regions of chromosome with different densities. 
 
3.4. Expression weighted network analysis predicts candidate genes influencing 
genome dysregulation. 
 
Noting the high level of dysregulation and clustering of genes according to their log2FC 
between the DS and control individuals, we next sought to determine the extent to which 
these gene expression changes impacts DS in a systems-level framework (i.e., construct 
interaction networks of co-expressed genes). To this aim, we performed a weighted gene co-
expression network analysis (WGCNA) on the bulk RNA-seq data from hippocampal and 




The WGCNA is a widely used method to identify clusters (modules) of genes with a similar 
level of expression among all the genes and under the assumption that they might thus be 
involved in similar biological processes and molecular pathways. The WGCNA analysis helped 
us to identify functionally related groups of genes influenced by DS. Overall, we found 19 
modules for the human hippocampus (Figure 3.15) and 13 modules for the human cortex 
(Figure 3.16), including a module for each brain region where the grouped genes did not 
belong to any other module. We tested for association against some biological traits (i.e., 
control or DS group, age, and sex) or technical trait (post-mortem interval (PMI)) for these 
modules. Overall, the modules significantly associated only with groups (control or DS), 
indicating that the disease status strongly influences them (healthy or DS) and not with any 
other biological trait that could affect the interpretation of our data. Notably, we found 6 
modules in the hippocampus which were significantly correlated with either control (G-HH-3, 
G-HH-4, G-HH-5) or DS samples (G-HH-1, G-HH-2, G-HH-6) (Figure 3.15) and 4 modules in the 





Figure 3.15. WGCNA-derived modules from human hippocampus gene expression data capture disease 
association. The modules were tested for association against Group (Control, DS), Age in years, post-mortem 
interval (PMI) in hours and Sex (F,M). The top numbers inside the heatmap show the color-coded (color bar on 
the right) Pearson’s correlation coefficient associated with each trait and the number in parenthesis indicate 
their statistical significance in terms of p-value. The black boxes represent the modules having statistically 
significant association with either group category (p<0.05, Pearson’s correlation test). G-HH represents gene 
modules in human hippocampus. 
 
 
Figure 3.16. WGCNA derived modules for human cortex gene expression data capture disease associations. 
The modules were tested for association against Group (Control, DS), Age in years, PMI in hours and Sex (F,M). 
The top numbers inside the heatmap show the color-coded (color bar on the right) Pearson’s correlation 
coefficient associated with each trait and the number in parenthesis indicate their statistical significance in terms 
of p-value. The black boxes represent the modules having significant association with either group category 
(p<0.05, Pearson’s correlation test). G-HC represents gene modules in human cortex. 
 
To understand the biological importance of the significant modules and their relevance to DS, 
we first performed a gene ontology (GO) analysis on the genes belonging to each of the 
modules. We found that the most significant upregulated module G-HH-1 (R=0.8, p=5 x 10-4) 
in DS hippocampus was enriched in locomotion, cell-cell adhesion, cell communication and 
also in a number of immune-regulated processes such as leukocyte-mediated immunity, 
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response to LPS, response to biotic stimulus and type I interferon signaling pathway (Figure 
3.17 left). This highlighted that G-HH-1 has biological importance in terms of immune 
response and cell communication. Interestingly, many of these latter processes were shared 
with the cortical module G-HC-1.  
 
On the other hand, the module G-HH-3, which is significantly correlated (R=-0.82, p=0.001) 
(Figure 3.14) with control samples (i.e. negatively correlated with DS samples), was enriched 
in biological processes such as ATP metabolic processes and electron transport chain (Figure 
3.17, right). This points to an association of this module with mitochondrial dysfunction. G-
HH-3 also showed significant enrichment in axonogenesis, neuron-projection development 
and synaptic signaling. Interestingly, module G-HH-3 shared some of these biological 
processes with the two downregulated modules from the cortex (G-HC-2 and G-HC-3; Figure 
3.17, right). Thus modules of co-expressed genes reflect enrichment in certain biological 





Figure 3.17. WGCNA derived co-expression modules associated with multiple GO terms. Multiple Biological 
Processes (BP), Cellular Components (CC) and Molecular Functions (MF) terms are enriched for significant 
modules from both human hippocampus and cortex gene expression data. The GO terms are separated by 
parenthesis, where orange represents biological processes, green represents cellular components and blue 
represents molecular functions. The region-wise modules are also separated by parenthesis, where purple 
shows hippocampus and pink shows cortex. The color bar on the right shows the range of significance defined 
by -log10FDR (after Benjamini-Hochberg multiple testing correction) for each term and each module. FDR: False 




To further resolve the biological impact of these significant modules from hippocampus and 
cortex, we investigated cell-type enrichment for each of these modules. Strikingly, we found 
that the upregulated hippocampal module, G-HH-1 (Figure 3.18 top) was specifically enriched 
in microglia. Another upregulated module, G-HH-2 was enriched in all the glial cell types 
(astrocytes, microglia and oligodendrocytes). Similarly, the upregulated module in cortex, G-
HC-1 (Figure 3.18 top) showed enrichment in only microglial cells. Conversely, the 
downregulated hippocampal module G-HH-3 (Figure 3.18 bottom) was enriched in neural cell 
types (pyramidal cells and interneurons), similar to the downregulated modules G-HC-3 and 
G-HC-2 from the cortex. We also found regional differences, implying that certain 
enrichments and dysregulation may potentially occur in specific regions in DS. For example, 
the upregulated module from hippocampus G-HH-6 had cell enrichment in oligodendrocytes 
and pyramidal cells (Figure 3.18 top) which was not present in any module originating from 
the cortical samples. Thus, markers and expression profiles of specific brain cell types from 
scRNA-seq data likely reflects sources of variation for each of the WGCNA-derived modules in 
DS. The enrichment for most of the upregulated modules in glial cells and downregulated 
modules in neural cells closely resembles the clear distinction observed at differential gene 





Figure 3.18. WGCNA derived co-expression modules capture differences in cell enrichment from both human 
hippocampus and cortex gene expression. They are separated by their enrichment in different cell types and 
divided in up- (top panel) or down-regulated modules (bottom panel). The color bars on the right for upregulated 
and downregulated modules are different and represent the fold enrichment. The region-wise modules are also 
separated by parenthesis, where purple shows hippocampus and pink shows cortex. The numbers inside the 
heatmap squares show the z-score (number of standard deviations away from mean) for  significant cell 
enrichment (Bootstrap significance testing with 100,000 repetitions)  G-HH: Gene module in Human 
hippocampus, G-HC: Gene module in Human cortex. 
 
All the above analysis indicated a high level of correlation between different modules from 
hippocampus and cortex which would make it easier to look for common pathways and genes 
involved in both the regions. We substantiated some of this correspondence between the 
region-wise modules with the help of a correlogram (Figure 3.19). We took the module 
membership value for each gene which is defined as the correlation of each gene within a 
module with the gene that most represents that specific module (known as module 
eigengene) and computed the correlation between the modules. We found that many 
modules were highly correlated between the hippocampus and the cortex. For example, 
modules G-HH-1 and G-HH-2 from hippocampus were significantly well correlated with G-HC-
1 from the cortex. To further corroborate our findings, we are currently comparing the results 
obtained by Olmos-Serrano et al. to our results. The authors analyzed DS and euploid control 
individuals from fetal to adult developmental stages in multiple brain regions with microarray 
technology (Olmos-Serrano et al., 2016). To compare our results, we need to select the age-
matched samples from the study mentioned above, considering that the genes analyzed by 





Figure 3.19. Module-based correlation in gene expression from human hippocampus and cortex. Correlation 
analysis among all the modules derived from the WGCNA analysis for protein coding genes from hippocampus 
and cortex shows some correlated modules. The red color indicates positive correlation, green indicates anti-
correlation and white indicates no correlation. Numbers inside the boxes are the correlation values for only 
statistically significant correlations (p<0.05, Pearson’s Correlation test). The entity of the correlation is 
represented by a color bar on the right. G-HH: Gene module in Human hippocampus, G-HC: Gene module in 
Human cortex.  
 
Next, we analyzed the specific genes involved in each of the significant modules from the 
WGCNA analysis by making a gene-gene interaction network using Cytoscape (Shannon et al., 
2003). Cytoscape is a tool used to visualize the gene-gene interaction network of co-
expressed genes. This interaction network allowed us to investigate hub genes that could 
regulate or be responsible for some of the defects and disturbances we observed in various 
biological processes and functions when we compared DS people samples to those of 
controls. As module sizes had a broad range and, in general, high numbers of genes, we only 
focused on the top (those with the highest module membership within each module) 20 
genes for each module for the Cytoscape analysis. In particular, to identify hub genes in each 
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module, we created a network from these 20 genes considering their number of connections 
(degree, denoted by the size of the nodes in the network, Figure 3.20) and the degree of gene 
expression (denoted by log2FC). For example, in the hippocampal module G-HH-1 having 607 
members (Figure 3.20A), six genes out of the top 20 consisted of C1QC, CD14, CD300A, IL4R, 
SERPINA1, OSMR, which are involved in the complement system, cytokine signaling, and 
immune response signaling pathways. This enrichment of hub genes to immune pathways 
was consistent with the module’s high association with microglia (Figure 3.19), the brain’s 
immune cells. This upregulated module G-HH-1 has few triplicated genes in the top hub 
genes, potentially responsible for some of the dysregulation in the rest of the genes from the 
same module. On comparing the G-HH-1 module with cortical module G-HC-1 (Figure 3.21A), 
we found out that none of the network-driving genes (hubs) are the same, and only one of 
them, ITGB2, is triplicated. On the other hand, in the hub genes from both hippocampal 
module G-HH-3 (Figure 3.20B) and cortical module G-HC-2 (Figure 3.21B), four genes (VDAC2, 
SCG5, GAP43, and REEP1) are common. All these results suggest that there could be 
potentially different drivers or hubs for each region, depending on which group of genes and 




Figure 3.20. Gene-gene interaction network for WGCNA-derived significant modules from hippocampus gene 
expression data comprising of the top 20 genes. The size of the nodes denotes the degree of connectedness, 
the color of the node (coded in the color maps below) represents the log2FC. A) Upregulated modules G-HH-1 
and G-HH-2 B) Downregulated modules G-HH-3 and G-HH-5. Number of genes in each module are denoted in 




Figure 3.21. Gene-gene interaction network for WGCNA-derived significant modules from cortex gene 
expression data comprising of the top 20. The size of the nodes denotes the degree of connectedness, the color 
of the node (coded in the color maps below) represents the log2FC. A) Upregulated modules G-HH-1 and G-HH-
2 B) Downregulated modules G-HH-3 and G-HH-5. Number of genes in each module are denoted in the brackets.  




Next, to validate DGE results, we performed real-time PCR on selected genes from different 





Figure 3.22. Correlation between RNA-seq and qPCR results. Significant correlation is observed between RNA-
seq data (y-axis) and qPCR (x-axis) after performing validation for some of the triplicated genes and other non-
triplicated, dysregulated genes showing fold-change comparison. The line represents linear regression with 
intercept at 0 and it shows a significant correlation R = 0.633 (p=0.001, Pearson’s Correlation test).  
 
3.5. Dysregulation in DS present also at transcript level. 
 
One of the outstanding questions in transcriptomics is whether the information generated by 
analysis at the level of total gene expression (commonly referred to as gene) by standard RNA-
seq techniques replicates changes at the level of transcript isoforms  (commonly referred to 
as transcripts). With the advent of more advanced technology for RNA sequencing, reduction 
in cost and increase in the number of reads that could be sequenced in a short time has 
provided the much-needed evidence that both gene-level and transcript-level changes reflect 
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both similar and distinct functional characteristics (Gandal et al., 2018). More than 95% of the 
human genome undergoes alternative splicing, thus often resulting in more than one mature 
RNA (mRNA) from each gene. These different transcript isoforms code for different protein 
isoforms when translated. Thus, in order to find out whether there is any dysregulation at the 
transcript level in DS vs. control and whether this disturbance in transcript expression 
matches the observations at gene-level differential expression, we expanded our differential 
gene expression analysis to transcript level on the same datasets and followed a similar 
pattern of analysis as we did for gene-expression. We first considered the differential 
transcript expression (DTE) and found 2627 and 2463 up-and down-regulated transcripts 
from 1954 and 2078 genes, respectively, in the hippocampus. In the cortex, we identified 
2858 and 1860 up-and down-regulated transcripts corresponding to 2076 and 1610 genes, 
respectively (Figure 3.23).  
 
There were fewer differentially expressed transcripts common between the hippocampus 
and the cortex in comparison to DEGs. In particular, we found only 393 and 613 common up 
and downregulated transcripts, respectively. Nevertheless, we found an increase in the 
number of differentially expressed triplicated transcripts compared to DEGs with 77 DE 
transcripts for the hippocampus and 190 in the cortex. These were corresponding to 50 genes 
for the hippocampus and 88 genes for the cortex. They were thus similar in number to DEGs, 
but they were not identical genes. In contrast to what we described at the gene level, the 






Figure 3.23. Transcript expression dysregulation in brain samples from individuals with DS. Venn diagram of 
differentially expressed transcripts in human hippocampus and cortex reveals common and non-common 
upregulated, downregulated and triplicated transcripts between the hippocampus and cortex.  
 
Also, when we compared the log2FC (calculated between DS and control samples) (Figure 
3.24), for the protein-coding genes and transcripts, we found a more extensive range of log2FC 
for both upregulated transcripts (right side of the curve in Figure 3.24A & B) and 
downregulated transcripts (left side of the curve). This reflects more considerable differences 
(between DS and control samples) when analyzing at the level of transcripts vs. genes. This 
observation, along with the attenuated cross-region overlap (Figure 3.23) at the transcript 





Figure 3.24. Larger range of fold changes for transcripts vs. genes. The log2FC of all the identified genes and 
transcripts in the human hippocampus and cortex reveals larger range of fold changes for transcripts vs. genes. 
This density plot represents the number of genes with a certain distribution of log2FC, and shows higher range 
of fold changes for transcripts (darker colors) in comparison to gene (lighter colors) for both A) hippocampus 
(violet) and B) cortex (pink). FC: Fold change. 
 
3.6. Differentially expressed transcripts play important roles in many biological 
processes similar to differentially expressed genes. 
 
As for DEGs, we also performed a Gene Ontology (GO) analysis on DE transcripts to determine 
the biological importance of these dysregulated transcripts. We found similar biological 
processes, cellular components, and molecular functions involved in both hippocampus and 
cortex when looking at the up-or down-regulated transcripts (Figure 3.25), as we had found 





Figure 3.25. Differentially expressed transcripts show region-wise conserved and specific GO terms. Gene 
ontology analysis for differentially expressed transcripts in hippocampus and cortex shows some overlapping 
terms and few specific ones. On left, the GO analysis for upregulated transcripts and on right, for downregulated 
transcripts. Purple dots represent hippocampus and pink dots represent cortex. BP: Biological Processes, CC: 
Cellular Components, MF: Molecular Function, FDR: False Discovery Rate 
 
Similar to gene-level expression changes, we performed cell-type enrichment analysis for the 
DE transcripts (Figure 3.26) and found many similarities but few inconsistencies between the 
gene and transcript levels. In the hippocampus, for both upregulated and downregulated 
transcripts, we found significant enrichment for all the five cell types with higher values in 
microglia and oligodendrocytes for upregulated transcripts and higher values in interneurons, 
pyramidal cells, and oligodendrocytes in downregulated transcripts. On the other hand, the 
results for the cortex were more consistent with what we found at the gene level, but again 
with enrichment in oligodendrocytes for both up-and down-regulated transcripts. This 
observation suggests a dysregulation in all cell types in the hippocampus at the transcript 
77 
 
level and the cortex. There is consistent dysregulation in the neural-immune trajectory at the 
transcript level as observed at the gene expression. One unique feature from transcript level 




Figure 3.26. Differentially expressed transcripts show cell-type enrichment in human DS hippocampus and 
cortex. Cell-type enrichment represented by fold enrichment for the upregulated (top panel) and 
downregulated (bottom panel) transcripts in different cells for hippocampus and cortex. The numbers in the 
heatmap represent the z-score (number of standard deviations away from mean) for the significant cell 
enrichment (Bootstrap significance testing with 100,000 repetitions).  
 
Further, we compared (Figure 3.27) the differentially expressed genes and transcripts for both 
the regions and found many transcripts that did not show DGE. These isoform-only DE genes 
(1489 in hippocampus and 1350 in the cortex) do not have changes at the gene-expression 
level where the expression is cumulative of all the transcripts of one particular gene, but 
rather the increase or decrease in expression is in the different transcript isoforms. This point 
further highlights the fact there are differences at the transcript level that are not present at 






Figure 3.27. Venn diagram of all the differentially expressed genes and transcripts reveals common and non-
common genes  in A) human hippocampus and B) cortex DGE: Differential Gene Expression, DTE: Differential 
Transcript Expression. 
 
3.7. Alternative splicing is responsible for generating multiple biologically important 
isoforms in DS. 
 
To identify the underlying regulatory mechanisms and the differences we observed between 
the gene and transcript expression profiles in DS, we examined the role of splicing. Alternative 
splicing can generate diverse mRNA isoforms using a combination of alternative exons. We 
analyzed six different kinds of splicing events: alternative 5’ and 3’ splice sites, exon skipping, 
microexons, mutually exclusive exons, and intron retention. We performed alternative 
splicing analysis on hippocampus and cortex RNA sequencing data using a recently developed 
method, “Vast-tools,” which calculates all the above mentioned splicing events. Splicing is 
calculated in terms of percent spliced-in (PSI) value, and the difference in the PSI for the same 
exon between two groups (in our case DS and controls) is known as deltaPSI. We found a large 
number of differential splicing events in both hippocampus and cortex. Overall, intron 
retention (IR) and exon skipping (SE) were the two most abundant events, and we focused 
our further analysis on these two kinds of events (Figure 3.28). 
 
Exon skipping events consist of microexon events (these are the events where the exon's size 
is between 3-27 bp). So, we pooled these microexon events (Figure 3.28) together with the 
rest of the exon skipping events to finally get 888 events originating from 771 genes in the 
hippocampus (Figure 3.28). We also found few triplicated genes to have exon skipping events 
associated with them (Figure 3.29, red lines and numbers). We then functionally 
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characterized by GO analysis the differential exon skipping events. Only in the hippocampus, 
we found significant enrichment for axon and dendrite formation, protein localization, 
protein phosphorylation, and synaptic signaling (Figure 3.30) across upregulated events 
defined by PSI (DS) > PSI (control) (Figure 3.29). Overall, we had similar observations for the 
cortex, too, with 1086 exon skipping events in 837 genes (Figure 3.28) and enrichment in 
biological processes such as locomotion and stress fiber assembly. When we observed the 
downregulated events defined by PSI (DS) < PSI (Control) (Figure 3.29), we found no biological 
processes which were only specific to the hippocampus (Figure 3.30). However, it shared 
many processes and cellular components with the cortex, such as neurogenesis, 
neurotransmitter secretion as biological processes, cell-substrate junction, microtubule, 
nucleoplasm, and vesicle membrane as cellular components. The downregulated exon 
skipping events in the cortex was important for axon guidance, cell communication, CNS 
development, cilium morphogenesis, locomotion, protein transport, and synaptic signaling. 
Overall, exon skipping events in the cortex were responsible for many biological processes. 
Together, these results suggest that splicing dysregulation is a shared phenomenon between 
the two regions and is highly important in DS. The genes that are differentially spliced mostly 
corresponded to multiple steps involved in brain development. 
 
Figure 3.28. Distribution of alternative splicing events which were significant with |dPSI| >10 in both 
hippocampus and cortex. IR: Intron Retention, MIC: microexon, SE: Skipped exon, ALTA (3’): Alternative acceptor 





Figure 3.29. Overlap of differentially spliced exon skipping events. Venn diagram shows the overlap between 
Hippocampus and Cortex for the A) upregulated, B) downregulated and triplicated differential exon skipping 
events. Red numbers and lines indicate number of triplicated genes found in the respective overlaps. PSI: 
Percent spliced-in index, DS: Down syndrome. 
 
 
Figure 3.30. Differentially spliced exon skipping events show region-wise conserved and specific GO terms. 
Gene ontology analysis for significant exon skipping events in hippocampus and cortex shows biological 
importance for genes having less exon skipping in DS samples (PSI (DS) > PSI (Control)) on left and for genes 
having more exon skipping in DS samples (PSI (DS) < PSI (Control)) on right. Purple dots represent hippocampus 
and pink dots represent cortex. BP: Biological Processes, CC: Cellular Components, MF: Molecular Function, FDR: 
False Discovery Rate 
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Next, we performed cell-type enrichment analysis on the significant skipped exon events from 
both regions (Figure 3.31). We observed that there was a broad cell-type enrichment except 
in microglia. This result suggests that splicing dysregulation might be more reflective for 
neural lineage, which produces neurons, astrocytes, and oligodendrocytes, rather than the 
hematopoietic lineage, which is responsible for generating microglia. 
 
 
Figure 3.31. Differentially spliced exon skipping events show cell-type enrichment in human DS hippocampus 
and cortex. Cell-type enrichment analysis reveals enrichment for upregulated and downregulated exon skipping 
events in different cells for hippocampus and cortex. The numbers in the heatmap represent the z-score 
(number of standard deviations away from mean) for the significant enrichment (Bootstrap significance testing 
with 100,000 repetitions). The top panel indicates enrichment for exon skipping events where PSI (DS) > PSI 
(Control) while bottom panel represents events with PSI (DS) < PSI (Control). PSI: Percent Spliced-In. 
 
When we performed the same analysis on spliced genes characterized by intron retention, 
we found 2181 events from 1708 genes in the hippocampus, where only 175 events were 
downregulated in DS samples and 1728 events from 1368 genes in the cortex with 362 events 
downregulated (Figure 3.28, 3.32). Very few of these events were associated with triplicated 
genes (Figure 3.32, red lines and numbers). As the number of downregulated events was far 
less than the upregulated events, and it was impossible to perform GO analysis on fewer 
downregulated events, we decided to pool all the genes with a dysregulation in intron 
retention for further biological analysis. Gene ontology (GO) analysis on these differentially 
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spliced intron retention events revealed that they were involved in cilium organization, 
macromolecule modification, regulation of GTPase activity processes, and localized in 
microtubule, nuclear lumen, and postsynaptic density for both hippocampus and cortex. 
Specifically, in the hippocampus, they are involved in RNA localization, RNA splicing, and ion 
binding and in the cortex, in macromitophagy, mitosis, neurogenesis, neurotransmitter 
secretion, and kinase activity (Figure 3.33). Overall, in this RNA study, we provided the first 





Figure 3.32. Overlap of differentially spliced intron retention events Venn diagram shows the overlap between 
Hippocampus and Cortex for the upregulated, downregulated and triplicated differential intron retention 
events. Red numbers and lines indicate number of triplicated genes found in the respective overlaps. PSI: 





Figure 3.33. Differentially spliced intron retention events show region-wise conserved and specific GO terms. 
Gene ontology analysis for significant intron retention events in hippocampus and cortex shows specific and 
common GO terms. Purple dots represent hippocampus and pink dots represent cortex. BP: Biological Processes, 
CC: Cellular Components, MF: Molecular Function, FDR: False Discovery Rate 
 
3.8. RNA-binding Proteins regulates alternative splicing and are dysregulated in DS. 
 
Extensive alteration of splicing is often controlled by RNA binding proteins (RBPs). Indeed, 
RBPs can impact alternative splicing by enhancing or repressing exon inclusion to generate 
multiple RNA transcripts and impact the overall gene expression. Thus, we looked at the RBPs, 
which were differentially expressed in DS and could influence the alternative splicing of 
specific genes that we found to be differentially expressed either at gene or transcript level. 
To this aim, we downloaded a list of RNA-binding proteins from the literature (Gerstberger et 
al., 2014) obtained by a detailed manual curation of all the known RBPs in the human genome. 
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First, we checked the expression of the RBPs from the literature list in our results on DGE and 
DTE from the hippocampus. From this list of 1542 RBPs, which represents ~7.5% of protein-
coding genes, we found several RBPs to be either DGE (445) or DTE (420) in our samples 
(Figure 3.34). Seven RBPs belonged to triplicated genes at the DGE level and three at the DTE 
level. ADARB1, responsible for A to I RNA editing, is the only RBP that originates from chr21 
and present at the differential gene and transcript levels. 
 
Similarly, in the cortex, we found several RBPs to be either DGE (492) or DTE (311) (Figure 
3.34). Nine RBPs are triplicated at DGE level and nine at DTE level, and interestingly, all of 
them were the same at both gene and transcript level. Although, at least for now, we do not 
follow the effect of these differentially expressed RBPs on the dysregulation we already 
observed in DS at gene and transcript level, it is clear that the number of RBPs we found to 
be differentially expressed are many and could potentially impact the expression levels of a 
large number of genes. 
 
 
Figure 3.34. Overlap of 1542 RBPs with the differential expressed genes and transcripts in A) hippocampus and 
B) cortex reveals differentially expressed RBPs at gene and transcript level. DGE: Differential Gene Expression, 
DTE: Differential Transcript Expression, RBP: RNA Binding Protein. Red numbers and lines indicate number of 
triplicated genes found in the respective overlaps. 
 
Next, we also looked at whether these RBPs were differentially spliced too in the 
hippocampus. Here, we focused only on those genes which were skipping exons, excluding 
other kinds of alternative splicing events for simplicity. In the hippocampus, we found 63 
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differentially spliced genes encoded by RNA binding proteins, among which 12 were 
differentially expressed at the gene level and 25 at the transcript level. When we overlapped 
differentially spliced RBPs to DGE and DTE, we found 9 RBPs (Figure 3.35A), PRPF18, 
MRPS18C, MRPL47, EIF4G3, ADARB1, PTBP2, TCERG1, DIS3, and PRPF40A. Among these, 
again, ADARB1 is the only triplicated RBP that is also differentially spliced. 
 
 
Figure 3.35. Overlap of differentially expressed RBPs at gene and transcript level with differentially spliced 
genes with exon skipping event in A) Hippocampus and B) Cortex reveals those RNA binding proteins which are 
differentially spliced by exon skipping event. DGE: Differential Gene Expression, DTE: Differential Transcript 
Expression, RBP: RNA Binding Protein, SE: Skipped Exon, Diff splice: Differentially spliced. 
 
Among the overlap, we also found polypyrimidine tract binding protein 2 (PTBP2). PTBP2 
belongs to a family of multifunctional RBPs, which play a significant role in tissue-specific 
transcriptional programs. PTBP2 is a crucial regulator of alternative splicing in neural 
progenitors and immature neurons. Most importantly, PTBP2 is known to be enriched in 
neurons and involved in axonogenesis (Zhang et al., 2019). This was particularly interesting 
considering our DTE results associated with cytoskeleton and axon formation to be 
differentially spliced.  
 
Similarly, in the cortex, we assessed whether the differentially expressed RBPs were also 
differentially spliced. We found 25 RBPs to be differentially spliced at the gene level and 18 
RBPs at the transcript level (Figure 3.35B). In the overlap between differentially spliced RBPs 
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to DGE and DTE, we found 11 RBPs, which are SRRM2, TCERG1, RBM3, PRPF18, YTHDC2, 
MRPS18C, MRPL33, EIF4G3, DAZAP1, G3BP2, and CELF2. None of these were triplicated.  
 
With multiple lines of evidence at gene, transcript, and alternative splicing level in 
hippocampus towards dysregulation in axon formation (Figures 3.5, 3.17, 3.25, and 3.30), we 
decided to validate some of the exon-skipping events in human hippocampal samples with 
semi-quantitative PCR (Figure 3.36). Among all 888 exon skipping events from 771 genes, we 
selected those genes involved in axon formation and one of the RBPs, PTBP2, which is known 
to act on these genes and is itself alternatively spliced (Figure 3.35A). These results confirmed 
that alternative splicing is involved in genes responsible for axon formation and is highly 
dysregulated in DS. 
 
 
Figure 3.36. Semi-quantitative PCR validation and quantitation for some genes involved in axon formation, as 
indicated by the experiments performed in Figures 3.5, 3.17, 3.25 and 3.30 confirmed that axonogenesis related 
genes are differentially spliced and PTBP2 may be responsible for this effect. A) Agarose gel images for each 
gene with 6 control and 6 DS hippocampal samples. B) Quantitation of the two bands for each gene to calculate 
amount of splicing denoted by PSI. All the quantitations are significant (p<0.05, student’s t-Test) PSI: Percent 
spliced-in index, ANK3: ankyrin 3, CD46: cluster of differentiation 46, MARK2: Microtubule affinity regulating 






3.9. Protein expression alteration provide another point of view for DS. 
 
Differential gene or transcript expression often results in proteins that are also differentially 
expressed. This is because alternative splicing results in different transcripts for a gene, 
producing protein isoforms with different functions and possible changes in the expression 
levels.  So, to complement our results from RNA sequencing, we compared the transcriptome 
with proteome. First, we performed proteomics on the same set of samples for both 
hippocampus and cortex. After PCA analysis and hierarchical clustering, we obtained the 
same samples as we obtained in RNA sequencing, confirming the consistency in the samples 
we selected (6 samples each for control and DS individuals for hippocampus and 8 samples 
each for cortex). 
 
Next, we performed differential expression analysis on both the hippocampus and cortex 
proteomic data (Figure 3.37). We found 741 and 417 up and down-regulated proteins in the 
hippocampus and 542 and 487 up and down-regulated proteins in the cortex. Overall, we 
found 285 upregulated proteins common between the two regions and 142 overlapping 
downregulated proteins. Some triplicated proteins were also differentially expressed, but 





Figure 3.37. Venn diagram of differentially expressed proteins from hippocampus and cortex shows common, 
non-common upregulated, downregulated and triplicated proteins between hippocampus and cortex. 
 
3.10. Multiple biological processes are dysregulated at protein level. 
 
Next, we performed the Gene Ontology analysis and looked for enrichment in various 
biological processes, organelle localization, and molecular functions. The upregulated 
proteins in the hippocampus and cortex indicated enrichment in viral process, transport, 
translation, response to unfolded protein, protein targeting to ER, protein complex 
biogenesis, and many other shared processes between the two regions (Figure 3.38). Only 
cell-substrate junction was shared between the hippocampus and cortex in all the cellular 
components for upregulated proteins. The downregulated proteins from both regions 
showed enrichment in neurotransmitter secretion, synaptic signaling, and synaptic vesicle 
transport (Figure 3.39). In terms of cellular components, the downregulated proteins showed 





Figure 3.38. Differentially expressed upregulated proteins show region-wise conserved and specific GO terms. 
Gene ontology (GO) analysis for upregulated proteins for both hippocampus and cortex shows some overlapping 
terms and few specific ones. Purple dots represent hippocampus and pink dots represent cortex. BP: Biological 





Figure 3.39. Differentially expressed downregulated proteins show region-wise conserved and specific GO 
terms. Gene ontology (GO) analysis for downregulated proteins for both hippocampus and cortex shows some 
overlapping terms and few specific ones. Purple dots represent hippocampus and pink dots represent cortex. 




We next performed EWCE analysis to look for overrepresentation in different cell types. The 
upregulated proteins in the hippocampus showed enrichment in all cell types. (Figure 3.40, 
top). On the other hand, the upregulated proteins from the cortex showed similar enrichment 
to upregulated genes, i.e., in all the glial cells. The downregulated proteins from the 
hippocampus and cortex were enriched in interneurons and pyramidal cells (Figure 3.40, 
bottom), similar to what we observed at the gene level. Nevertheless, this analysis’s most 
striking observation was the enrichment in oligodendrocytes that we found for both the 
upregulated and downregulated proteins in both regions, suggesting a high dysfunction 
taking place in these cells. This observation is supported by a previous study highlighting the 
role of oligodendrocytes dysregulation in DS (Olmos-Serrano et al., 2016). 
 
 
Figure 3.40. Differentially expressed proteins show cell-type enrichment in human DS hippocampus and 
cortex. Cell-type enrichment reveals differences among the upregulated (top panel) and downregulated 
(bottom panel) proteins in different cells for hippocampus and cortex. The numbers in the heatmap represent 
the z-score (number of standard deviations away from mean) for the significant enrichment (Bootstrap 
significance testing with 100,000 repetitions).  
 
3.11. Co-expression analysis helps identify drivers of proteome dysregulation. 
 
At the gene level, we observed that the co-expression network analysis arranged the genes 
into clusters related to function, cellular location, and cell types. We wanted to investigate 
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whether the protein level information provided us with somewhat similar observations. We 
performed Weighted Protein Co-expression Network Analysis (WPCNA) and found many 
protein modules associated with DS. We identified 16 modules from the hippocampal 
samples (Figure 3.41) and 14 from the cortical samples (Figure 3.42). We found three 
upregulated modules (P-HH-2, P-HH-4, P-HH-5) and three downregulated modules (P-HH-1, 
P-HH-3, P-HH-6) to be significantly associated with DS and control individuals, respectively in 
the hippocampus (Figure 3.41). While, there were two modules (P-HC-1, P-HC-3) associated 
with DS and three modules (P-HC-2, P-HC-4, P-HC-5) associated with control samples in the 
cortex (Figure 3.42). None of these significant modules were influenced by the other 
biological (age and sex) or technical (PMI) factors. 
 
 
Figure 3.41. WPCNA-derived modules from human hippocampus protein expression data capture disease 
association. The modules were tested for association against Group (Control, DS), Age in years, post-mortem 
interval (PMI) in hours and Sex (F,M). The top numbers inside the heatmap show the color-coded (color bar on 
the right) Pearson’s correlation coefficient associated with each trait and the number in parenthesis indicate 
their statistical significance in terms of p-value. The black boxes represent the modules having significant 





Figure 3.42. WPCNA-derived modules from human cortex protein expression data capture disease association. 
The modules were tested for association against Group (Control, DS), Age in years, post-mortem interval (PMI) 
in hours and Sex (F,M). The top numbers inside the heatmap show the color-coded (color bar on the right) 
Pearson’s correlation coefficient associated with each trait and the number in parenthesis indicate their 
statistical significance in terms of p-value. The black boxes represent the modules having significant association 
with either group category (p<0.05, Pearson’s correlation test). P-HH represents protein modules in human 
hippocampus. 
 
We next sought to determine the biological significance of these significant modules from the 
hippocampus and cortex. Similar to gene ontology analysis performed on data from modules 
derived from gene-expression experiments, we performed the same analysis on the modules 
from proteomics data for both regions. We found that the upregulated modules P-HH-2, P-
HH-4, P-HH-5 from hippocampus and P-HC-1, P-HC-3 from cortex showed significant 
enrichment in extracellular vesicle (Figure 3.43 left). Moreover, four of these upregulated 
modules from both the regions showed enrichment in cell-substrate junction. This highlighted 
that the upregulated modules might be involved in cell-cell communication, which usually 
occurs with the help of vesicles released by the cells or establishing contact between different 
cell types.  
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On the other hand, the downregulated protein modules from the hippocampus, P-HH-3, and 
cortex, P-HC-2 (Figure 3.43 right) shared many biological processes and cellular components 
(e.g., antigen processing and presentation, membrane fusion, neurogenesis, 
neurotransmitter secretion, protein transport, synaptic signaling, cell-substrate adhesion). 
Interestingly, many downregulated modules from both regions showed enrichment in 
extracellular vesicles similar to upregulated modules. This suggests that the cell 





Figure 3.43. WPCNA derived co-expression modules associated with multiple GO terms. Multiple Biological 
Processes (BP), Cellular Components (CC) and Molecular Functions (MF) terms are enriched for significant 
modules from both human hippocampus and cortex protein expression data. The GO terms are separated by 
parenthesis, where orange represents biological processes, green represents cellular components and blue 
represents molecular functions. The region-wise modules are also separated by parenthesis, where purple 
shows hippocampus and pink shows cortex. The color bar on the right shows the range of significance defined 
by -log10FDR (after Benjamini-Hochberg multiple testing correction) for each term and each module. FDR: False 
Discovery Rate, P-HH: Protein module in Human hippocampus, P-HC: Protein module in Human cortex. 
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We further resolved the biological significance of these significant modules by determining 
their enrichment with cell-type-specific profiles in the brain (Figure 3.44). Upregulated 
protein modules for both hippocampus and cortex were broadly significant in all cell types. 
This result is consistent with the modules obtained from protein coding-genes at the RNA 
level. Moreover, the downregulated protein modules in both hippocampus and cortex were 
significantly associated with neural cell types such as interneurons and pyramidal cells, similar 
to our observations from modules derived from gene-expression data. Interestingly, one 
module from hippocampus P-HH-3 and cortex P-HC-2 were also associated with 
oligodendrocytes. 
 
Figure 3.44. WPCNA-derived modules capture differences in cell enrichment from both human hippocampus 
and cortex protein expression. They are separated by their enrichment in different cell types and divided in up- 
(top panel) or down-regulated modules (bottom panel). The color bars on the right for upregulated and 
downregulated modules are different and represent the fold enrichment. The region-wise modules are also 
separated by parenthesis, where purple shows hippocampus and pink shows cortex. The numbers inside the 
heatmap squares show the z-score (number of standard deviations away from mean) for only significant cell 
enrichment (Bootstrap significance testing with 100,000 repetitions). P-HH: Protein module in Human 
hippocampus, P-HC: Protein module in Human cortex.  
 
On seeing a considerable overlap between biological processes, cellular components, and cell 
enrichment between the modules from the proteomic experiments, we prepared a 
correlogram to find out how much correlation was present between each module from both 
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hippocampus and cortex (Figure 3.45). The correlation significance was tested using 
hypergeometric Fisher’s exact test, and the modules showed a high (red), anti (green), and 
low (white) correlation in protein membership. We found a high correlation (R=0.7, p=0.01) 
between P-HH-3 and P-HC-2, consistent with the biological and cell enrichment we observed 
previously. 
 
Figure 3.45. Module-based correlation in protein expression from human hippocampus and cortex. 
Correlation analysis among all the modules derived from the WPCNA analysis for proteins from hippocampus 
and cortex shows correlation among them. The red color indicates positive correlation, green indicates anti-
correlation and white indicates no correlation. Numbers inside the boxes are the correlation values for only 
statistically significant correlations (p<0.05, Pearson’s Correlation test). The correlation is represented by a color 
bar on the right. P-HH: Protein module in Human hippocampus, P-HC: Protein module in Human cortex.  
 
Similar to the data derived from gene expression experiments, we created protein-protein 
interaction networks from the top 20 proteins for each significant module to identify the 
driving proteins (hubs) in the network (Figure 3.45 and 3.46). We did not find many triplicated 
proteins among the top hubs in many modules. We found only one triplicated protein, 
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TRAPPC10, in the hippocampal upregulated protein module P-HH-5 with 120 members 
(Figure 3.46A). In the upregulated modules from the cortex's protein expression data, the P-
HC-3 module had three triplicated proteins, COL18A1, COL6A1, and COL6A2, whereas P-HC-1 
had two triplicated proteins, APP and S100B (Figure 3.47A). As we observed from Figure 3.45, 
there were very few well-correlated modules from the two regions. Moreover, we did not 
observe any common hub genes from the upregulated modules from the hippocampus and 
cortex.  
 
On the other hand, the downregulated module P-HH-3 (Figure 3.46B) was correlated well with 
P-HC-2 (Figure 3.47B), as previously observed. These two modules from the hippocampus and 





Figure 3.46. Protein-protein interaction for WPCNA-derived significant modules from hippocampus protein 
expression data shows the top 20 proteins. The size of the modes denotes the degree of connectedness, the 
color of the node (coded in the color maps below) represents the log2FC. A) Upregulated modules P-HH-5, P-HH-
4 and P-HH-1  B) Downregulated modules P-HH-6, P-HH-1 and P-HH-3. Number of proteins in each module are 
denoted in the brackets.  Asterisks denote triplicated proteins. P-HH: Protein module in human hippocampus, 





Figure 3.47. Protein-protein interaction for WPCNA-derived significant modules from cortex protein 
expression data shows the top 20 proteins. The size of the modes denotes the degree of connectedness, the 
color of the node (coded in the color maps below) represents the log2FC. A) Upregulated modules P-HC-3 and 
P-HC-1  B) Downregulated modules P-HC-5, P-HC-2 and P-HC-34. Number of proteins in each module are 
denoted in the brackets.  Asterisks denote triplicated proteins. P-HC: Protein module in human cortex, FC: Fold 
change. 
 
3.12. Alterations at the levels of RNA and protein expression are largely distinct. 
 
The number of proteins identified in the proteomic analysis was much less than the number 
of protein-coding genes identified through RNA-seq. Even though fewer proteins are detected 
in proteomics, there are still around 3800 proteins common between both technologies for 
which we had expression values. We thus investigated how expression changes at the RNA 
level correspond with protein level changes in DS vs. control brains. We plotted the log2FC for 
all genes common between RNA and protein data for both hippocampus and cortex and 
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found very little correlation between the two (Figure 3.48A, B). On the other hand, there is a 
high correlation when we compare the two regions either at RNA level (0.9) or protein level 
(0.5) separately (Figure 3.43C). This result suggests that although overall RNA and protein are 
poorly correlated, but comparing the two regions at either RNA or protein level individually, 
there is a high cross-region overlap. 
 
 
Figure 3.48.  Low correlation between RNA and protein for both regions but high cross region correlation at 
RNA and protein level. Correlation plot shows low correlation between RNA and protein for hippocampus and 
cortex but high cross-region correlation at both RNA and protein. A) Plot shows correlation between RNA and 
protein for all  common genes between RNA and protein for the hippocampus with r=0.129 (p=0.001, Pearson’s 
correlation test) and B) for the cortex with r=0.198 (p=0.001, Pearson’s correlation test). x-axis represents log2FC 
from proteomics data while y-axis represents log2FC from gene expression data. The line represents linear 
regression with intercept at 0. Red dots represent genes with differential expression at both RNA and protein 
level, orange dots represent differentially expressed genes only, blue dots represent differentially expressed 
proteins only and gray dots represent non differentially expressed genes or proteins. C) Correlations at RNA and 
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protein levels for both hippocampus and cortex. The color bar on right in C represents the correlation from -1 
to 1. FC: Fold change. 
 
To further elaborate on these similarities and differences between the two omics 
(transcriptome and proteome) and the two regions (hippocampus and cortex), we compared 
their biological processes, cellular locations, and molecular functions (Figure 3.49). We pooled 
together all the gene ontology analyses previously performed for both the regions at the RNA 
and protein level to perform this comparison. Interestingly, even with a low level of 
correlations at expression levels and module levels, we found many processes and functions 
to be shared between the two regions and two technologies. For example, in terms of 
biological processes, transport, translation, neurotransmitter secretion, neuron 
development, and axon development were represented by many datasets (Figure 3.49 left). 
At the cellular component level, we found overlap for cell-substrate junction and extracellular 
vesicle (Figure 3.49 right). This was consistent with our observations from modules derived 




Figure 3.49. Comparison of all the enriched gene ontology terms for both RNA and protein and for both 
hippocampus and cortex reveals a multiple similarities and distinctions. On left, we show the biological 
processes and on right, the molecular functions and cellular components for the differentially expressed genes 
and proteins separated by their expression level (up- or downregulated) and region (hippocampus and cortex). 
The GO terms are separated by parenthesis, where orange represents biological processes, green represents 
cellular components and blue represents molecular functions. The color bar on the right shows the range of 
significance defined by -log10FDR (after Benjamini-Hochberg multiple testing correction) for each term and each 
module. FDR: False Discovery Rate 
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3.13. microRNA analysis reveals post-transcriptional regulation in DS.  
 
Our data from both hippocampus and cortex at both RNA and protein levels revealed a highly 
complex and non-trivial scenario, suggesting that many similarities and dissimilarities exist 
between the two regions and at multiple levels of expression. To target any gene or protein 
and/or biological process or pathway would require a careful and thorough understanding of 
the genetic regulation taking place in DS. To further resolve these multiple levels of genetic 
regulation in DS, we look at another class of gene-expression regulators, the microRNAs. 
 
microRNA (miRNAs) represent one of the fundamental regulatory pathways of RNA and 
consequent protein expression. miRNAs post-transcriptionally regulate protein-coding genes. 
miRNAs either degrade the mRNA or inhibit protein translation through complementary 
binding at 3’ untranslated region (3’UTR) of mRNA. As we observed huge dysregulation in 
gene and protein expression in DS vs. control samples in hippocampus and cortex, this 
encouraged us to look at mRNA-miRNA and miRNA-protein relationships. We first performed 
small RNA sequencing and obtained around 7 million reads for each sample. Similar to gene 
and protein expression, we filtered the samples according to PCA, hierarchical clustering, and 
RIN values and again obtained the same set of hippocampal and cortical samples. The 
majority (~ 27%) of small RNA reads corresponded to miRNA reads, followed by ~21% transfer 
RNA (tRNA) reads, 10% small nucleolar RNAs (snoRNA) reads, and the rest were distributed 
among other small RNAs or remained unmapped. 
 
Here, we focused on miRNA reads. We filtered the miRNAs according to the criteria that in 
both control and DS brains, at least 5 samples from the hippocampus (total samples were 6 
each) and at least 7 samples from the cortex (total samples were 8 each) should express the 
miRNA to remove the lowly expressed miRNAs. Thus, we obtained ~700 miRNAs for each 
brain region. We performed differential expression analysis on these miRNAs after 
normalization of each sample and found 32 differentially expressed miRNAs (DEmiRNAs) in 
the hippocampal samples (Figure 3.50) and 50 in the cortical samples (Figure 3.51). Among 
these DEmiRNAs, 6 of them were shared between the two regions, miR-155-5p, miR-99a-3p, 




From previous studies, we know that five miRNAs (miR-155, miR-802, miR- 125b-2, let-7c, and 
miR-99a), which are derived from chromosome 21, are overexpressed in the hippocampus 
and frontal cortex of DS fetuses (Hill and Lukiw, 2016; Zhao et al., 2015). Here in the 
hippocampus and cortex from adult DS individuals, we found four of them to be differentially 
expressed except miR-802 in the hippocampus (Figure 3.50) and two (miR-155 and miR-99a) 
in the cortex (Figure 3.51).  
 
 
Figure 3.50. Several miRNAs were differentially expressed in the hippocampus. Volcano plot shows the 
differentially expressed miRNAs identified in the hippocampus upon differential expression analysis. The level 
of expression changes for each miRNA is shown in Log2FC and their level of significance in -log10FDR. The vertical 
dotted line represents 0, a point on the x-axis which shows upregulated miRNAs in red on the right side and 
downregulated miRNAs in blue on the left side. The horizontal line denotes the -log10FDR=1.3 which represents 
the FDR<0.05. The grey dots show non differentially expressed miRNAs. FDR: False discovery rate, hsa-miR: 




Figure 3.51. Several miRNAs were differentially expressed in the cortex. Volcano plot shows the differentially 
expressed miRNAs identified in the cortex upon differential expression analysis. The level of expression changes 
for each miRNA is shown in Log2FC and their level of significance in -log10FDR. The vertical dotted line represents 
0, a point on the x-axis which shows upregulated miRNAs in red on the right side and downregulated miRNAs in 
blue on the left side. The horizontal line denotes the -log10FDR=1.3 which represents the FDR<0.05. The grey 
dots show non differentially expressed miRNAs. FDR: False discovery rate, hsa-miR: human microRNA.    
 
The rest of the other differentially expressed miRNAs in our study were found to be located 
on other chromosomes. In particular, many downregulated miRNAs were located on 
chromosome 14, and many upregulated miRNAs were located  on chromosome X in both 
regions.  
 
3.14. Differentially expressed miRNAs have a large repertoire of differentially 
expressed targets. 
 
As miRNAs are known to regulate multiple genes by binding to their 3’UTRs, we searched for 
mRNA targets for each DEmiRNAs in the TargetScan v7.2 in the  3’UTRs of about 20,000 genes. 
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First, we downloaded a list of all conserved miRNA sites in the vertebrates for the conserved 
miRNA families and filtered the data for our DEmiRNAs. On average, we obtained 4400 mRNA 
targets for our DEmiRNAs. We then filtered the targets according to their correlation with 
miRNA expression level by keeping only those inversely-correlated targets to the expression 
of miRNAs. 
 
We classified the targets into three categories (Figure 3.52): a) differentially expressed at both 
gene and protein expression levels, which we denoted as “Both” (Figure 3.52A, C); b) 
differentially expressed at least at gene level, which we denoted as “RNA” (Figure 3.52A, B); 
and c) differentially expressed at least at protein level, which we denoted as “Protein” (Figure 
3.52A, D). Next, we calculated which miRNAs had the most number of differentially expressed 
targets from each of these three categories. We reasoned that those miRNAs with the most 
number of targets could act as hub miRNAs.  
 
 
Figure 3.52. Schematic of classification of inversely correlated miRNA targets. A) Venn diagram shows overlap 
of DEmiRNA-DEgenes with DEmiRNA-DEproteins, where blue circle shows only RNA level inverse correlation, 
purple circle shows only protein level inverse correlation and the overlap between the two circles shows miRNA 
inverse correlation with both differentially expressed genes and proteins. B) miRNAs targeting only genes, 
denoted as “RNA”, C) miRNAs targeting both genes and proteins, denoted as “Both” and D) miRNAs targeting 
proteins only, denoted as “Protein”. In B), C) and D) yellow triangles represent differentially expressed miRNAs, 
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blue circles represent differentially expressed genes and purple circles represent differentially expressed 
proteins. DE: Differentially expressed. 
 
Among the miRNAs upregulated in the hippocampus, we found miR-181-5p involved with 
many differentially expressed targets either at RNA level or protein level, followed by miR-92-
3p and 374c-5p (Figure 3.53A). On the other hand, in the miRNAs downregulated in the 
hippocampus, miR-132-3p/212-3p and miR-221-3p/222-3p had the most number of 
differentially expressed targets (Figure 3.53B). Like upregulated miRNAs in the hippocampus, 
the targets of upregulated miRNAs in the cortex were mostly targeted by miR-181-5p, 
followed by the miR-15-5p family miR-186-5p (Figure 3.53C). In the targets obtained from 
downregulated miRNAs in the cortex, miR-124-3p came out as the hub miRNA (Figure 3.53D). 
So, overall, we found many hub miRNAs targeting multiple differentially expressed genes or 





Figure 3.53. miRNA target prediction reveals the top hub miRNAs with the most number of differentially 
expressed targets. A) miRNAs upregulated in hippocampus B) miRNAs downregulated in hippocampus (C) 
miRNAs upregulated in cortex and D) miRNAs downregulated in cortex. For all heatmaps, the top miRNAs are 
those with the most number of differentially expressed targets. The color bar on the right of each heatmap 
represents the range of the number of differentially expressed targets. Here, miRNAs targeting both genes and 
proteins, denoted as “Both”, miRNAs targeting only genes, denoted as “RNA” and miRNAs targeting proteins 
only, denoted as “Protein”. miR: microRNA. 
 
To investigate the biological significance of the targets of the DEmiRNAs, we performed GO 
analysis on the targets (Figure 3.54). We found enrichment in biological processes such as 
axonogenesis, neurogenesis, developmental process, and locomotion. We found high 
enrichment in nucleoplasm and transcription-factor activity among the cellular components 
and molecular functions, respectively.  
 
We also found many KEGG pathways enriched in the targets predicted from upregulated 
miRNAs in both hippocampus and cortex (Figure 3.55). Ras signaling, Rap1 signaling, PI3K-AKT 
signaling, axon guidance, focal adhesion, and regulation of actin cytoskeleton. On the other 
hand, there were fewer pathways for downregulated miRNA targets, for example, Wnt 
signaling for targets of miRNAs downregulated in the hippocampus and axon guidance for 
targets of miRNAs downregulated in the cortex. Overall, our results suggest that DEmiRNAs 
could be responsible for some differential expression at gene and protein levels in DS 








Figure 3.54. Enrichment of targets of differentially expressed miRNAs in multiple Biological Processes (BP), 
Cellular Components (CC) and Molecular Functions (MF) terms. The GO terms are separated by parenthesis, 
where orange represents biological processes, green represents cellular components and blue represents 
molecular functions. The enrichment for targets of up and downregulated miRNAs are separated by 
hippocampus (purple parenthesis) and cortex (pink parenthesis). The color bar on the right shows the range of 
significance defined by -log10FDR (after Benjamini-Hochberg multiple testing correction) for each term. FDR: 




Figure 3.55. Numerous KEGG pathways show enrichment for targets of differentially expressed miRNAs. The 
enrichment for targets of up and downregulated miRNAs are separated by hippocampus (purple parenthesis) 
and cortex (pink parenthesis). The color bar on the right shows the range of significance defined by -log10FDR 
(after Benjamini-Hochberg multiple testing correction) for each term. KEGG: Kyoto Encyclopedia of Genes and 
Genomes, FDR: False Discovery Rate. 
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3.15. Multiple axons phenotype in Ts65Dn hippocampal primary culture. 
 
Different analysis throughout our study pointed to dysregulation in genes related to axon 
formation. To test if there is any defect in axon formation, in vitro, we cultured primary 
hippocampal neurons from Ts65Dn and wildtype (WT) mouse brains. We performed 
immunocytochemistry analysis by staining with AnkG (a marker of axon initial segment), Pan-
Nav (another protein located in axon initial segment), and Map2 (dendritic marker). We 
observed several neurons with three different phenotypes in both cultures: a) neurons with 
no axons, b) neurons with single axons, and c) neurons with two or more axons (Figure 3.56A). 
We compared the neurons from these two genotypes and counted the number of neurons 
with a different number of axons and the length of the axons.  
 
We found that the length of axons with only a single axon in the neuron was similar in both 
genotypes. In comparison, the neurons with multiple axons were longer in Ts65Dn vs. WT 
(Figure 3.55B). We also observed that Ts65Dn culture had ~30% neurons with two or more 
neurons compared to 18% neurons from WT. Also, there were 20% neurons from Ts65Dn 
with no visible axons (Figure 3.55C). These are preliminary results, but they confirm a 







Figure 3.56. Presence of multiple axons in hippocampal primary culture from Ts65Dn mice. A) Representative 
confocal images of Pan-Nav, AnkG and Map2 stained hippocampal primary culture at days in vitro (DIV) 14 from 
WT and Ts65Dn mice. Scale bar: 20µm. White arrows in the merged image show the neurons with multiple 
axons. B) Quantification of the length of the axons from neurons with single or multiple axons as in figure A 
expressed in mm. Bars represent the average length of each axon ± SEM in all analyzed images and circles 
represent the single axons  from all experiments (12 fields total/genotype, 2 coverslips each, N=2). ** p<0.001, 
Mann-Whitney U test. C) Quantification of percentage of neurons with multiple axons in all analyzed images, 
where black bars represent WT and grey bars represent Ts65Dn. The numbers inside the bars show number of 
neurons having no axons, single axons and multiple axons across all the analyzed experiments (12 fields 
total/genotype, 2 coverslips each, N=2). ***p<0.0001, ****p<0.00001, multiple t-test followed by Holm-Sidak 





A key issue in designing therapeutic interventions for neurodevelopment disorders such as 
Down syndrome (DS) is the lack of knowledge and understanding of their underlying 
mechanisms. Rather than focusing on specific candidate triplicated genes or proteins, we 
followed a systematic transcriptome and proteome-wide approach. We leveraged the 
benefits of total RNA-seq, small RNA-seq, and proteomics and performed these analyses on 
the same set of post-mortem human DS brains and their age-/sex-matched healthy controls. 
This integrative analysis reduced the potential bias observed when performed isolated single 
analysis on different samples. While several other single transcriptomic and proteomic 
studies on DS have provided important clues mostly on the developing brain (Gonzales et al., 
2018; Guedj et al., 2016; Huo et al., 2018; Stamoulis et al., 2019; Waugh et al., 2019), our 
study is the first, to our knowledge, to implement an integrative approach on adult human DS 
brains.  
 
The intense focus on studying and targeting neurodevelopmental diseases (NDDs) early in life 
is a reasonable approach. The underlying rationale is that early in life intervention may correct 
the developmental trajectory and alleviate behavioral phenotype later in life. However, 
findings from DS mouse models have shown that environmental or pharmacological 
interventions could reverse molecular, electrophysiological, and behavioral phenotypes even 
in adulthood (Bianchi et al., 2010; Contestabile et al., 2013; Deidda et al., 2015; Fernandez et 
al., 2007; Parrini et al., 2017; Savardi et al., 2020). Thus, therapeutic approaches in adults 
complementary to early interventions should also be investigated.   
 
We also analyzed mRNA transcript (isoform) level expression and identified alternative 
splicing, RNA binding proteins, and miRNAs as crucial intermediate regulatory steps in DS. Our 
data provide molecular information signatures that consistently repeat at gene, transcript, 
and protein levels and may function as critical players in DS pathophysiology.  
 
As DS is such a complex genetic condition, we should tackle this complexity at multiple levels, 
such as at different ages, brain regions, and at different layers of genetic regulation. Finally, 
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results from other neurodevelopmental disorders such as autism spectrum disorder, which 
has been studied more extensively with a large cohort of samples, have provided details 
about individual genetic variations and suggest following further studies in DS with a larger 
number of individuals. Thus this may inspire a new layer for therapeutic approaches to aid 
people with DS in their daily life challenges.   
 
4.1. Gene expression dysregulation in NDDs: 
 
We demonstrated a large number of differentially expressed genes in both hippocampus and 
cortex of people with DS compared to controls. We mapped these differentially expressed 
genes onto their chromosomal locations. Along with triplicated genes, we found many non-
triplicated dysregulated genes suggesting a genome-wide disturbance in DS. All the 
chromosomes were found to harbor genome-wide dysregulation domains (GEDDs), as 
previously observed in fibroblasts and iPSC from DS fetuses (Letourneau et al., 2014). 
According to their expression, the differentially expressed genes were associated with specific 
biological processes and could be further partitioned into disease-specific pathways and 
specific cell types. We found an association of the upregulated genes with immunological 
pathways and glial cells (astrocytes, microglia, and oligodendrocytes) in the hippocampus and 
cortex.  
 
Conversely, we observed a predominant association of the downregulated genes with 
neurological pathways and neural cells (interneurons and pyramidal cells). Interestingly, 
autism spectrum disorder (ASD), schizophrenia (SCZ), and bipolar disorder (BP) cortices show 
the same preference of up-and down-regulated genes for immune and neural pathways 
(Gandal et al., 2018). In particular, upregulation of astrocytes was observed in SCZ and BP and 
astrocytes and microglia in ASD. Moreover, the interferon response pathway was significantly 
more upregulated in ASD. Thus, these observations suggest the neural-immune trajectory is 
dysregulated in different neurodevelopmental and neuropsychiatric disorders and may 
provide new targets for molecular interrogation.  
 
We also observed region-specific biological processes, cellular components, and molecular 
functions for the differentially expressed genes among the shared enrichments. These 
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differences between the two regions were also observed in brains from healthy controls and 
in individuals with ASD, SCZ, and epilepsy (Collado-Torres et al., 2019; Ramasamy et al., 2014). 
These observations from our results and literature suggest differences in development and 
functions of both hippocampal and cortical neural circuits (Sousa et al., 2017) and could 
coincide with the heterogeneity in the different cell types present in these regions (Bayraktar 
et al., 2014; Böttcher et al., 2018; Buosi et al., 2018; Matias et al., 2019). 
 
The cell type enrichment analysis on gene expression data from both hippocampus and cortex 
was consistent with our previous study with fewer human hippocampus samples from DS 
individuals (Pinto et al., 2020). In our previous study, we observed microglia activation and an 
increase in the number of microglia upon performing immunohistochemical analysis on tissue 
obtained from DS hippocampus vs. control. When we performed cell-type enrichment on the 
gene expression results from the previous study, we found enrichment of upregulated genes 
in the microglia. This led us to reason that cell-type enrichment on other brain regions might 
also inform us about the molecular pathology and the proportion of different cells. This 
rationale is consistent with the observation of dynamic alteration of different cell types in DS 
studies (Griffin et al., 1989; Pinto et al., 2020; Wierzba-Bobrowicz et al., 1999). For example, 
in an earlier study on DS fetuses, a reduction in the number of neurons in the hippocampus 
was observed (Guidi et al., 2008). Additionally, an increase in astrocyte number was observed 
in the DS hippocampus and frontal lobe in early development (Zdaniuk et al., 2011). In the 
case of Ts65Dn, an increase in GFAP-positive astrocytic cells is observed in the hippocampus 
during early development, but in adult animals, a decrease in GFAP transcript expression has 
been reported (Contestabile et al., 2007; Toso et al., 2008).  
 
4.2. Gene expression driven co-expression networks in DS: 
The brain is a complex organ, consisting of multitudes of cell types, trillions of connections 
between them, and performing many functions essential for cognition. So, defining the 
molecular network involved in this complex structure is highly important to better understand 
the pathophysiology of the diseases and design new and more efficacious therapeutic 
approaches. Consequently, we divided gene expression profiles from both regions into co-
expression modules. We annotated significant gene-expression driven modules with 
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biological processes, cellular components, and molecular functions along with individual cell 
types. The shift from looking only at differentially expressed genes to complete gene 
expression profile follows our observation that there is a genome-wide dysregulation in DS, 
influencing the expression of non-triplicated and triplicated genes alike. Multiple studies 
related to brain diseases have applied this strategy of organizing gene expression into clusters 
(modules)  (Gandal et al., 2018; Parikshak et al., 2015, 2016). In particular, gene clusters have 
been used to identify genes whose expression differs between different conditions across 
developmental trajectories, brain cells, and regions (Hawrylycz et al., 2012; Kang et al., 2011; 
Oldham et al., 2008). The co-expression clusters approach has enabled a much better 
understanding of diverse diseases than an approach based on looking at only specific genes. 
For example, Gandal et al., with the help of a co-expression study in ASD at both gene and 
transcript expression levels, have refined the molecular signatures of glial-immune 
dysregulation so much so that they were able to identify microglial, astrocytic, and interferon 
response specific modules along with synaptic vesicle cycle and neural activity-dependent 
modules.   
We used the robustly defined co-expression clusters to identify hub genes that could be 
responsible for driving the disease in the hippocampus and cortex individually. Different 
biological processes and cell types defined the clusters for each region. Many modules from 
the hippocampus and cortex shared biological or cell enrichment, and we observed a high 
correlation between some of these modules from the two regions. In this regard, we observed 
that modules derived from the two regions retained the same cell-specific enrichment, even 
though the top hub (gene) driving these modules were different in both regions. Interestingly, 
the hub genes in the upregulated modules are not only triplicated but also the non-triplicated 
ones too. This finding raises an important question that whether targeting non-triplicated 
genes, which is the downstream effect of triplication, could help rescuing cognitive 
impairment observed in DS. 
 
Furthermore, we found very few hub genes shared between the two regions. For instance, 
non-triplicated gene, GAP43, expressed at neuronal growth cones, is one of the hub members 
of downregulated hippocampal module G-HH-3 and cortical module G-HC-2. Usually, GAP43 
is expressed highly in the hippocampus and cortex, two regions implicated in learning and 
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memory (Holahan and Routtenberg, 2008; Rekart et al., 2005). It is also involved in 
neurodevelopment as its knockout leads to embryonic lethality, with only 5-10% survival to 
adulthood (Metz and Schwab, 2004). It plays a vital role in axon guidance (Donovan et al., 
2002; Shen et al., 2002) and it is associated with brain diseases (Bogdanovic et al., 2000; Tian 
et al., 2007). GAP43 also enhances long-term potentiation (Hulo et al., 2002), impaired in DS 
(Contestabile et al., 2017). 
 
On the other hand, we found a couple of region-specific modules, hippocampal modules G-
HH-6 and G-HH-4, which appeared to reflect dysfunction in microtubule organization and 
protein localization. Indeed, ADGRG1, a hub (non-triplicated) gene in the upregulated 
module, G-HH-6, is a G-protein coupled receptor and interacts with RhoA to stabilize the 
oligodendrocyte development (Ackerman et al., 2018). Interestingly, this module enriched in 
oligodendrocytes. Another example is the TAX1BP1 gene, one of the hub genes of 
downregulated hippocampal module G-HH-4. This gene is involved in proteotoxicity due to 
the accumulation of ubiquitin conjugates in the mouse brain upon its loss (Sarraf et al., 2020). 
Interestingly, disruption in proteostasis and protein quality control in lymphocytes obtained 
from DS individuals has been observed (Aivazidis et al., 2017). The above finding represents 
an axis of neurodevelopmental architecture that pertains to protein translation and 
degradation. Notably this is under the control of integrated stress response in DS (Zhu et al., 
2019).   
 
Moreover, we observed that a large proportion of significant modules are enriched for 
different cell types. This may depend on changes in expression for genes associated with 
these cells or just simply reflect shifts in the proportions of the numbers of specific cells in DS 
as discussed previously.  
 
4.3. Transcript expression alterations in DS: 
 
Gene expression is an accumulation of transcript-level expression. Thus, classical RNA-seq 
gene expression studies lose many changes at the transcript level, which might be highly 
important. We evaluated differential transcript expression by mapping the RNA-seq reads 
onto the transcriptome. This analysis provides an opportunity to find molecular interactions 
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that were not visible at the gene level (Pelechano et al., 2013). One of the most important 
observations from this comparison at gene and transcript expression levels was that the 
transcripts had a more extensive range of fold changes than gene expression in DS vs. control 
individuals. In the cell type enrichments for the differentially expressed transcripts, we found 
high enrichment for oligodendrocytes for all the differentially expressed transcripts for both 
hippocampus and cortex. The oligodendrocyte enrichment likely relates to the observation 
made by Olmos-Serrano et al. regarding impairment in oligodendrocyte development and 
myelination in DS (Olmos-Serrano et al., 2016).  
 
Moreover, the differentially expressed transcripts were less overlapping between the two 
regions than differentially expressed genes. This regional heterogeneity between 
hippocampus and cortex has been observed in SCZ (Collado-Torres et al., 2019). Transcript 
expression also showed many biological processes, cellular components, and molecular 
functions distinct from the gene expression level. For example, the hippocampus had 
upregulated transcripts that showed enrichment in axonogenesis, adherens junction 
assembly, myelination, phosphorylation, trans-Golgi network, and cadherin binding not 
present at the gene level. Again this phenomenon of enrichment for specific biological 
processes in different brain regions has been observed previously (Collado-Torres et al., 
2019). 
 
Among the downregulated transcripts, mitotic cell cycle, sister chromatid segregation, RNA 
splicing, microtubule, and peroxisome were few of the transcript-specific enrichments. Few 
of these signatures for downregulated transcripts were observed partially in ASD, SCZ, and BP 
(Gandal et al., 2018). Moreover, the neural-immune signature originating from differential 
transcript expression was more prominent for the cortex, as the hippocampus showed 
enrichment in all the cell types. This neural-immune heterogeneity between two different 
regions of the brain has, until now, not been observed. 
 
This observation again highlights the importance of transcript expression, which may unveil 
the regional heterogeneity much better than gene expression profiles. The difference 
between gene and transcript expression has been observed in the cortices from ASD, SCZ, 
and BP. However, there is no evidence of comparison between different regions from 
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neurodevelopment disorders for differences in gene and transcript expression. Therefore, 
further studies such as the one discussed here are needed to make a systematic comparison 
between different brain regions for neurodevelopmental disorders at both gene and 
transcript level, to understand the regional heterogeneity and find molecular targets that 
could have local (region-specific) effect or a global effect (brain-wide). 
 
4.4. Alternative splicing and RNA binding proteins: 
Alternative splicing is a main regulatory pathway which generates transcript isoforms. Robust 
evidence from literature suggests the importance of alternative splicing and RNA binding 
proteins in neurological disorders (Da Cruz and Cleveland, 2011; Fromer et al., 2016; Irimia et 
al., 2014; Jaffe et al., 2018; Parikshak et al., 2016). Given the functional importance of 
alternative splicing, recent studies have taken tremendous efforts both experimentally and 
computationally to annotate and predict different splicing events in the analyzed tissue 
(Braunschweig et al., 2014; Irimia et al., 2014; Tapial et al., 2017; Yeo et al., 2004). We 
observed several differentially expressed transcripts in DS vs. controls for both the regions. In 
particular, by analyzing alternative splicing events, we provided a potential of uncovering 
splicing defects and the master regulators (e.g., RNA-binding proteins and components of the 
spliceosome machinery) that may play essential roles in DS. For example, we found evidence 
of dysregulation in axonogenesis and dendritic-spine development-related genes in both 
hippocampus and cortex. Broadly, for genes undergoing alternative splicing in the form of 
exon skipping, we found enrichment in cell projection morphogenesis, axonogenesis, 
dendrite morphogenesis, synaptic signaling, postsynaptic density, microtubule, and 
contractile fiber. This result underscores previous findings linking alternative splicing to 
cytoskeleton-related genes (Zhang et al., 2016). For example, the authors found evidence of 
splicing dysregulation in genes responsible for microtubule dynamics (Mast2, Mark4), focal 
adhesion (Macf1) and postsynaptic density (Dlg4, Homer). Moreover, converging evidence 
from other neuropsychiatric and neurodevelopmental disorders suggests impairment in 
synapses maintenance due to dendritic spine morphogenesis dysregulation (Engle, 2010; Lo 
and Lai, 2020; Nakai et al., 2018) including DS people and mouse models (Benavides-Piccione 
et al., 2004; Cramer and Galdzicki, 2012; Haas et al., 2013; Pinto et al., 2020).  
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Another kind of alternative splicing event we found in our study is intron retention. Intron 
retention (IR) leads to multiple distinct fates of the transcript. It could lead to degradation via 
nonsense-mediated decay or via interaction with miRNA-RISC complex as 3' untranslated 
region (UTR) of mature transcripts with intron retention will provide more miRNA binding 
sites. IR transcripts can also lead to different protein isoforms or be detained in the nucleus 
preventing translation (Monteuuis et al., 2019). We observed a large percentage of genes 
with intron retention in DS. We believe that some of these genes with high IR might explain 
the great variety of downregulated genes, transcripts, or proteins in DS. Thus this hypothesis 
warrants further analysis and experimental proof. 
 
RNA binding proteins (RBPs) are essential for multiple neurodevelopmental functions. 
Supporting this notion, we found PTBP2, an RBP, to be both differentially expressed and have 
exon 10 skipping in the DS hippocampus and cortex. PTBP2 regulates axonogenesis-related 
genes and it is a crucial regulator of alternative splicing in neural progenitors and immature 
neurons (Zhang et al., 2019). Consequently, we validated the accuracy of our results from 
alternative splicing analysis data by semi-quantitative PCR for PTBP2 and other axon 
formation-related genes (ANK3, MARK2, EML1 and CD46) that we found differentially 
expressed and differentially spliced in our gene expression and alternative splicing analysis. 
We are currently investigating the importance of PTBP2 and the other axon formation-related 
genes in axon formation in iPSCs derived neurons from DS and their isogenic control lines. 
 
Another exciting question worth exploring is the presence of differentially expressed RNA 
binding proteins, which play an essential role in alternative splicing. Also, the possibility that 
RNA binding proteins may be themselves differentially spliced is worth the investigation. 
Indeed in the neuronal progenitors, PTBP1, another RBP, induces the exclusion of exon 10 of 
PTBP2, leading to exon 10 skipping and a transcript with premature termination codon (Li et 
al., 2014b). By integrating a manually curated list of RBPs (Gerstberger et al., 2014) with the 
differentially expressed genes and transcripts, we found a large number of dysregulated RBPs 
in both hippocampus and cortex. Among the RBPs that we found differentially expressed at 
gene and transcript levels and triplicated in DS is ADARB1. This RBP is responsible for base 
changes from adenosine (A) to inosine (I) RNA editing, a co- or post-transcriptional 
mechanism of gene expression regulation (Eisenberg and Levanon, 2018). A-to-I editing 
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occurs within glutamate receptor 2 (GLUR2), which is an AMPA receptor mediating fast 
excitatory synaptic transmission (Sommer et al., 1991). Interestingly,  Gonzales et al. have 
recently quantified the A-to-I editing in trisomic and euploid cortical neurons derived from 
induced pluripotent stem cell (iPSC) lines. However, they could not observe any differences 
in the amount of RNA editing between the two experimental groups in the cortical neurons. 
They concluded that even though the ADARB1 is triplicated in the iPSC derived trisomic 
neurons, it does not lead to increase in global levels of RNA editing (Gonzales et al., 2018). In 
addition, analysis of specific sites (the site of action of ADARB1) in glutamate receptor 
subunits (GLUR2, GLUR5 and GLUR6) in brains (cortex, cerebellum and cerebral white matter) 
of both DS and healthy control individuals from fetuses, neonates and adults, there was no 
increase in expression of ADARB1 and no alteration in editing (Kawahara et al., 2004). These 
observations could suggest that there is no role of RNA editing in DS, but further experimental 
validations are needed to thoroughly conclude it in our study. 
 
Furthermore, we extended our analysis by identifying a few RBPs that were differentially 
expressed at both gene and transcript levels and had an exon skipping event associated with 
them (i.e. one of their exon was differentially skipped in either DS or control individuals). 
Among those proteins, we found EIF4G3 in both hippocampus and cortex. EIF4G3 is a critical 
scaffold protein implicated in protein complexes implied in translation initiation. In DS brain 
samples, we found a  microexon excluded in EIF4G3. Interestingly, EIF4G3 microexon  controls 
the expression of synaptic receptors linked to neuronal activity and cognitive functioning 
regulation. Also, depletion of EIF4G3 microexon can lead to social behavior, learning, and 
memory deficits (Gonatopoulos-Pournatzis et al., 2020). Understanding more thoroughly the 
regulation of alternative splicing in human brain tissue will be essential to add another layer 
of comprehension because the RBPs, components of spliceosome machinery, and various 
transcription factors regulate gene expression and can drive genotype to phenotype changes 
(Hsiao et al., 2016; Yang et al., 2019). 
  
4.5. Translating genotype to phenotype in DS: 
 
Proteins constitute the building blocks and functional machinery of the cell. The polygenic 
nature of neurodevelopmental disorders such as DS would benefit from an holistic approach 
123 
 
as the brain's core functions require an extensive network of protein-protein interactions. 
Measuring genes and RNA transcript isoforms is not sufficient and adequate to capture multi-
protein functional assemblies. Quantification of changes of protein levels in a 
neurodevelopmental disorder provides a complementary and direct approach to 
understanding the phenotype and underlying molecular pathology. Due to technological 
differences intrinsic to RNA-seq and proteomics, we identified fewer proteins vs. genes in our 
samples. First, any changes in gene expression may be either a cause or consequence of the 
disorder. Second, biological differences observed between gene and protein may be a 
limitation of proteomics data. Apart from a low number of proteins detected in MS, the less 
soluble and large membranous proteins are challenging to detect. These issues highlight why 
it is crucial to perform integrative multi-level analysis on the same set of samples to obtain 
complementary information and that critical aspects in both gene and protein expression 
analysis exist. 
 
Anyhow, even though we found fewer differentially expressed proteins in the hippocampus 
and cortex, they provided essential insights. Indeed, overall, there were more than 1000 
differentially expressed proteins and they were enriched in different biological processes, 
cellular components and molecular functions. Although many gene ontology terms were 
shared between the gene and protein expression some of them were distinct from gene 
expression data. For example, biological processes such as cell death, cellular response to 
stimulus, interferon gamma mediated signaling pathway, locomotion and mRNA splicing were 
specific to gene expression data. And antigen processing and presentation, cell junction 
assembly, cell-cell adhesion, coagulation and ion homeostasis were only present in the 
protein expression data. Interestingly, few of these enrichments from protein expression data 
were region-specific. For example, among upregulated proteins, cellular detoxification, 
fibrinolysis, wound healing, actin filament bundle and vesicle lumen in the cortex and axon 
development, coagulation, lipid oxidation, myelination, oxidative phosphorylation, cleavage 
furrow and respiratory chain complex in the hippocampus. Similarly, there were many terms 
from downregulated proteins specific to each region. 
 
Moreover, we observed the cell-type enrichment for the upregulated proteins in the 
hippocampus in all cell types, similar to our observation from transcript levels, but the 
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downregulated proteins in hippocampus were specific to neural cells. Conversely, the cortex 
showed specific enrichment i.e. the upregulated proteins were enriched in glial cells 
(astrocyte, microglia and oligodendrocytes) and the downregulated proteins were enriched 
in neural cells (interneurons and pyramidal cells).  Notably, the oligodendrocytes showed the 
enrichment for all the differentially expressed proteins in both regions. This observation could 
again be related to the oligodendrocyte dysfunction observed in DS brains throughout 
development (Olmos-Serrano et al., 2016). Similar observation at both gene and protein 
expression levels for the oligodendrocytes has also been described in schizophrenia (Martins-
de-Souza, 2010). There are multiple studies who took transcriptomics or proteomics 
approaches on different brain regions of adult individuals with schizophrenia and concluded 
with the same observation of oligodendrocyte dysfunction (Arion et al., 2007; Hakak et al., 
2001; Katsel et al., 2005; Martins-de-Souza et al., 2010; Pennington et al., 2008; Prabakaran 
et al., 2004; Tkachev et al., 2003). 
 
Further, comparing the expression level changes (log2FC for DS vs. control) of RNA and protein 
within one region resulted in a very low correlation for both the regions. This observation is 
in agreement with the multiple studies performed on multiple human tissues including 
different brain regions and cell types, suggesting a low correlation between RNA and protein  
(Liu and Aebersold, 2016; Mangleburg et al., 2020; Poulopoulos et al., 2019; Seyfried et al., 
2017; Sharma et al., 2015; Wang et al., 2019). In contrast, the expression level changes 
between DS vs. controls (log2FC) in only gene or only protein comparison between the two 
regions showed a high correlation. This result suggests a common molecular (gene or protein) 
signature exists for both regions in DS vs. controls that undergo different post-transcriptional 
and post-translational regulation within a region. This observation requires thorough 
validation from qPCR and western blot experiments in our study, and we are currently in the 
process of performing these experiments.  
 
Moreover, by weighted protein co-expression network analysis (WPCNA), we detected robust 
protein modules associated with DS, which were not conserved with gene expression derived 
modules. For example, in the cortex, proteomics modules did not include cell death, cell 
communication, leukocyte cell-cell adhesion, and many immune-related processes highly 
enriched in gene expression derived modules. Moreover, protein modules had hub proteins 
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different from hubs of the gene-expression modules. The hubs represented the biological 
enrichment for the whole module. For example, upregulated hippocampal module P-HH-2 
consisted of 6 hub (CAND1, NAE1, PSMA1, PSMA7, P4HB, PDIA6) proteins among the top 20 
which were involved in post-translational protein modification, which was not represented 
by the hubs from modules derived from gene expression data. This difference in hubs and the 
biological enrichments between gene and protein expression-derived modules suggests that 
we could obtain complementary information from both RNA-seq and proteomics approaches. 
One such study exist for DS, where the authors have profiled the neural progenitors and the 
differentiated neurons from iPSCs derived from trisomic and euploid control individuals at 
both transcriptome and proteome level. Although, the authors observed a high correlation 
between the RNA-seq and proteomics results with converging molecular pathways, unlike our 
own results. Nevertheless, they did not carry out a level of robust network analysis to identify 
the hub genes as we did. Still, they found 23 hub genes among which, APP (triplicated in DS) 
(Sobol et al., 2019), one of the hub proteins from our own analysis in the cortical module from 
protein expression data, P-HC-1. These results suggests that although there are few 
differences and similarities between the RNA and protein, taking an approach with multiple 
levels of analysis would lead to wider identification of hub genes or proteins. Moreover, these 
results indicated that the study of transduction regulatory events and mediators may hold 
the potential for a better understanding of the mechanisms underlying DS.  
 
4.6. miRNA regulatory relationships: 
 
Multiple factors could contribute to the differences between gene and protein expression 
changes of DS vs. control tissues. One could be differences in expression of non-coding RNAs, 
especially miRNAs known to degrade the transcript or inhibit translation upon binding at 
3'UTR of mRNAs (Bartel, 2004). By differential expression analysis, we found several 
differentially expressed miRNAs in DS vs. controls samples including few encoded on HSA21 
(let-7c-3p, miR-125-2-3p, miR-155-5p, miR-99a-3p). When we extended our analysis to look 
for miRNA binding sites in the differentially expressed genes and proteins, we obtained a few 
(32 in hippocampus and 50 in the cortex) differentially expressed miRNAs with many (1459-




Some of these DEmiRNAs with many differentially expressed putative targets play extensive 
roles and regulate the nervous system development, plasticity and function. For example miR-
34-5p regulates synaptogenesis in the neuromuscular junction of Drosophila larva (McNeill et 
al., 2020). miR-132 acts as an activity-induced miRNA that can regulate dendritic spine 
formation (Impey et al., 2010), and deletion of miR-132 and miR-212 in mice impairs synaptic 
plasticity (Remenyi et al., 2013). miR-181 controls neurites growth and promotes 
synaptogenesis in cortical neurons (Kos et al., 2016) and is involved in hippocampus-
dependent memory formation (Zhang et al., 2017). As potential hub regulators of 
transduction of multiple mRNAs into proteins, some miRNAs that we found commonly 
dysregulated in the cortex and hippocampus may become in the future novel therapeutic 
targets, as suggested by multiple studies having taken antisense oligo-based approaches to 
treat diseases (Bajan and Hutvagner, 2020; Roberts et al., 2020; Stenvang and Kauppinen, 
2008). 
 
We also observed targets for the differentially expressed miRNAs were involved in axon 
guidance and cytoskeleton regulation. When we investigated whether miRNAs could 
establish a regulatory network involving the RNA binding proteins implicated in alternative 
splicing and axon formation, we found one of the topmost influencing miRNAs in the 
hippocampus and cortex being miR-181-5p. miR-181-5p targets the RNA binding protein 
PTBP2. At both RNA and protein levels, we found downregulation of this RBP in DS vs. control. 
miR-181-5p has the complementarity in the 3'UTR of PTBP2 to possibly regulate the 
expression at both RNA and protein levels.  
 
4.7. Physiological consequences of defective neuronal polarization: 
 
Neuronal polarization involves the specification of a single axon and multiple dendrites in 
undifferentiated neurites (Arimura et al., 2009). Multiple studies in primary culture derived 
from mouse brains have shown that any perturbation in a specific set of genes responsible 
for neuronal polarization might lead to axons characterized by no axons or multiple axons.  
 
For example changes in expression of genes such as CRMP-2, PAR3, PAR6, CDC42, GSK3b, 
MARK2, SHTN1, LKB1 and p75 leads to differences in the percentage of neurons with no axons 
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or multiple axons (Gomis-Rüth et al., 2008; Shelly et al., 2010, 2011; Takano et al., 2017; 
Tortosa et al., 2017; Zuccaro et al., 2014). Interestingly, a recent study in primary culture from 
rat hippocampus has shown that the neurons with multiple axons are electrophysiologically 
functional with a functional axon initial segments (AIS). AIS is responsible for generating 
action potential and is enriched with sodium voltage channels. The authors found that sodium 
channels were closer to the soma in neurons with multiple axons. The depolarizing phase of 
the action potential was shorter compared to the single axon neurons. Although there were 
no differences in the whole-cell sodium currents and membrane properties, the change in the 
distribution of sodium voltage channels was enough to shorten the rising phase of the action 
potential leading to faster recruitment of somatic sodium channels.  
 
In our differential gene expression, alternative splicing, differential expression of RBPs, 
differential protein expression and targets for the differentially expressed miRNAs, there 
were genes involved in axon guidance and cytoskeleton regulation. Our first set of 
experiments in Ts65Dn murine hippocampal cultures revealed an increased number of 
neurons with multiple axons and an increased number of neurons with no axons in 
comparison to wild type culture. While the number of neurons with a single axon were 
decreased in Ts65Dn culture in comparison to wild-type culture. This supports the results by 
bioinformatics analysis on DS and control human brains and warrants further experiments in 
brain slices from Ts65Dn animals and in neurons derived from iPS cells from DS subjects. We 
are currently analyzing the RNA sequencing and proteomics results from the hippocampi and 
cortices derived from Ts65Dn and wild-type animals to know and understand if we observe 
similar expression changes in the mouse model.  
 
These findings of functional neurons with multiple AIS and defects in neuronal polarization 
due to perturbation in expression levels of essential polarizing molecules at  both gene and 
protein levels suggest that the phenotype of multiple axons we observe in our hippocampal 
culture derived from Ts65Dn mice might result from changes in expression of polarization 






Our study demonstrates that multi-omics systems biology approach can identify molecular 
drivers at multiple gene-regulation levels for specific biological processes and cell types. We 
demonstrate the ability to integrate gene and protein expression data with differential 
transcript expression and identification of alternative splicing, further increasing the ability of 
whole transcriptome analysis in discovering gene expression patterns within a context of a 
neurodevelopmental disorder. Our study represents a proof of concept of a new approach 
that may lead to a significant advance towards identifying better therapeutics by providing 
clues to how this data from DS and control individuals could be used as a resource to 
understand both disease and normal brain function. In our case, it indicated unexpected 
deficits in neuronal polarization and a general state of neuroinflammation. 
 
In our study, although within each group (Control and DS), the samples differ in terms of sex, 
race, age and PMI, it was not possible to analyse the results keeping all these parameters 
separate within a group because of the limited number of samples. So, future experiments 
may include a larger number of samples with more focus towards these biological and 
technical traits and performing both transcriptomics and proteomics across different ages, 
from fetuses to adulthood, to systematically obtain further biological insights into the 
development of the complex phenotype that characterize DS people. Another step forward 
would be to isolate other non-coding RNAs such as long non-coding RNAs and circular RNAs, 
providing further information at a diverse level of investigation and thus possibly new targets 
for future therapeutic approaches. Given the complexity of DS, a multilayer approach at 















Table 1: Sample and donor information for hippocampal samples (The samples in bold and 
red were removed based on PCA, hierarchical clustering and RIN values).  
 









Maryland 1841 C2 7.3 Hp Control M 19 14 White Natural 




Maryland 5606 C4 6.7 Hp Control F 35 2 White Accidental 
Maryland 4782 C5 6.7 Hp Control M 18 17 White Accidental 
Miami HCT17HFW_06 C6 2.7 Hp Control F 45 27.31 White Natural 




Pitt 13149 C8 5.8 Hp Control F 46 7.6 White Natural 
Pitt 13250 C9 3.0 Hp Control F 49 11.25 White Natural 
Maryland 5762 C10 3.5 Hp Control F 39 19 White Natural 
Maryland 5981 C11 5.5 Hp Control F 44 19 White Unknown 




Maryland 5277 Ds2 3.3 Hp DS M 19 26 White Natural 




Maryland 5005 Ds4 6.3 Hp DS F 39 12 White Natural 
Maryland M1960M Ds5 5.4 Hp DS M 19 14 Asian Natural 
Miami HBNY_18_02 Ds6 2.7 Hp DS F 51 8.26 White Natural 
Miami HBNU_18_04 Ds7 2.6 Hp DS M 57 11.2 White Unknown 
Pitt 13202 Ds8 6.5 Hp DS F 43 12.42 White Accidental 





















Table 2: Sample and donor information for cortical samples (The samples in bold and red were 
removed based on PCA, hierarchical clustering and RIN values). 
 





Miami HCT17HFW C12 2.1 Cortex Control F 45 27.31 White Natural 




Pitt 13149 C14 4.7 Cortex Control F 46 7.6 White Natural 
Pitt 13250 C15 3.1 Cortex Control F 49 11.25 White Natural 
Maryland 5889 C16 5.1 Cortex Control M 27 12 White Natural 




Maryland 5762 C18 4.4 Cortex Control F 39 19 White Natural 
Maryland 1668 C19 5.6 Cortex Control M 19 24 White Accidental 




Maryland 5235 C21 6.2 Cortex Control M 28 24 White Accidental 




Maryland 5981 C23 6.5 Cortex Control F 44 19 White Unknown 
Miami HBNY_18_01 Ds10 3.9 Cortex DS F 51 8.26 White Natural 
Miami HBNU_18_03 Ds11 2.9 Cortex DS M 57 11.2 White Unknown 
Pitt 13202 Ds12 6.0 Cortex DS F 43 12.42 White Accidental 
Pitt 13235 Ds13 5.8 Cortex DS F 44 6.53 White Natural 
Maryland 753 Ds14 5.7 Cortex DS M 23 24 White Natural 




Maryland 5005 Ds16 6.5 Cortex DS F 39 12 White Natural 
Maryland 5277 Ds17 2.9 Cortex DS M 19 26 White Natural 
Maryland 5341 Ds18 3.4 Cortex DS M 25 24  Natural 






































Sample Number of input reads Uniquely mapped reads (number) Uniquely mapped reads (%) Number of splices: Total
C1 117867083 111763397 94.82% 17584647
C2 106845629 101329716 94.84% 19857006
C3 105500435 93610678 88.73% 20793072
C4 113429363 103597616 91.33% 23391231
C5 96886236 91673407 94.62% 16091717
C6 108042553 95039843 87.97% 9784247
C7 113299122 103245807 91.13% 19179718
C8 127503211 116900932 91.68% 20780909
C9 106622384 98461971 92.35% 7892502
C10 99430536 89048100 89.56% 9935738
C11 99464380 90748808 91.24% 15150297
C12 90588269 81505761 89.97% 5578697
C13 91598455 84245097 91.97% 14793848
C14 91932859 83519541 90.85% 9305769
C15 97839416 84284628 86.15% 8033066
C16 102011726 89918963 88.15% 17433260
C17 107088974 93125289 86.96% 23489526
C18 106746420 95927148 89.86% 16573042
C19 114899095 105163970 91.53% 19726597
C20 115589683 104597983 90.49% 22425066
C21 106259871 95176864 89.57% 20131540
C22 134184901 122167226 91.04% 25294663
C23 117883109 108388722 91.95% 21877059
Ds1 96625379 86039522 89.04% 17101657
Ds2 91151812 83984223 92.14% 8331928
Ds3 72786555 67434677 92.65% 11108586
Ds4 101787323 92669101 91.04% 18047760
Ds5 105137325 96270115 91.57% 16087522
Ds6 109233617 100252668 91.78% 13772600
Ds7 98043649 89330308 91.11% 11486163
Ds8 104842912 97785977 93.27% 17695414
Ds9 100993469 87129144 86.27% 14571227
Ds10 106544929 93915984 88.15% 14922084
Ds11 104445945 82609678 79.09% 10803106
Ds12 105180273 93772158 89.15% 20480754
Ds13 107449618 96692469 89.99% 19243169
Ds14 113196633 100335858 88.64% 20489965
Ds15 114013839 104013280 91.23% 12971063
Ds16 101111732 86206962 85.26% 16547695
Ds17 113654447 99401525 87.46% 8146059
Ds18 94963002 81718054 86.05% 10747696
Ds19 104288488 91201640 87.45% 14949972
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Table 5. Number and size of GEDDs for each chromosome from hippocampus and cortex 








Table 7. List of antibodies used in the work.  
 
Name Host Source RRID Identifier Concentration 
AnkG Guinea pig Synaptic Systems AB_2737033 1:300 
Pan-Nav Mouse Sigma AB_477552 1:100 
Map2 Rabbit Covance AB_291679 1:250 
 
 
Chromosome Total GEDDs Size range Total GEDDs Size range
Chr1 148 2.2 Kb-25.67 Mb 210 2.73 Kb-25.64 Mb
Chr2 114 0.47 Kb-17.73 Mb 120 7.48 Kb-13.62 Mb
Chr3 82 11.33 Kb-23.68 Mb 93 5.38 Kb-32.37 Mb
Chr4 41 16.21 Kb-35.06 Mb 57 8.25 Kb-16.74 Mb
Chr5 55 5.15 Kb-42.44 Mb 77 0.09 Kb-27.63 Mb
Chr6 79 1.71 Kb-23.43 Mb 74 3.34 Kb-19.95 Mb
Chr7 65 3.93 Kb-15.33 Mb 84 8.05 Kb-14.44 Mb
Chr8 41 14.01 Kb-23.84 Mb 40 23.4 Kb-29.15 Mb
Chr9 45 19.51 Kb-27.13 Mb 68 0.99 Kb-27.9 Mb
Chr10 65 11.17 Kb-19.2 Mb 83 3.12 Kb-13.1 Mb
Chr11 77 3.05 Kb-13.69 Mb 85 0.22 Kb-16.26 Mb
Chr12 83 3.9 Kb-26.92 Mb 104 3.9 Kb-17.91 Mb
Chr13 23 85.64 Kb-23.17 Mb 29 25.61 Kb-42.19 Mb
Chr14 55 13.76 Kb-15.18 Mb 60 10.84 Kb-14.79 Mb
Chr15 67 11.05 Kb-6.01 Mb 73 9.71 Kb-6.3 Mb
Chr16 49 20.3 Kb-16.83 Mb 54 6.6 Kb-21.99 Mb
Chr17 81 3.25 Kb-6.56 Mb 99 2.4 Kb-6.38 Mb
Chr18 24 12.67 Kb-11.65 Mb 23 10.03 Kb-13.45 Mb
Chr19 43 4.08 Kb-10.25 Mb 85 1.86 Kb-6.61 Mb
Chr20 37 0.3 Kb-12.98 Mb 53 5.8 Kb-9.96 Mb
Chr21 7 127.66 Kb-9.73 Mb 5 195.32 Kb-20.17 Mb
Chr22 19 8.98 Kb-13.01 Mb 34 3.59 Kb-6.1 Mb
ChrX 56 43.11 Kb-34.88 Mb 66 8.27 Kb-28.45 Mb
Total 1356 1676
Hippocampus Cortex
Gene Event Product sizes (bp) Skipped exon size (bp) No. of PCR cycles Forward primer Reverse primer
ANK3 HsaEX0004153 132-195 63 40 ACTGTCACAGAGAAGCACAAA TTCCTTAAGGTCCTGTGGCCC
MARK2 HsaEX0037917 147-192 45 40 AATTTGCCCTACGGTGTGACC CTTTTCTTTGTCGTTGCCGCC
EML1 HsaEX0022329 146-203 57 40 CCCTGCCTTTAAGAACCACGG TCGTTCAGAAGAGCTGGTCCT
CD46 HsaEX0013872 132-177 45 40 ACAGTTATGTTTGAATGCGATAAGGG TGGAGGCTTGTAAGTAGGCCT
PTBP2 HsaEX0050732 127-161 34 35 GCTGGTGGCAATACAGTCCTG TGGTTTCCATCAGCCATCTGT
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Gene Sense Primer Anti-sense Primer slope Efficency % Efficency
hACTB CAGCAAGCAGGAGTATGAC GAAAGGGTGTAACGCAACT -3.242 103.45 2.03
hAGAP3 GTGAGTCCCATGTAAACTTTGT ACGCACACAGTCTGGTTT -3.4 96.84 1.97
hAKAP9 ACAACACATGGCACAGAT ATTAGTCCTAGTTCTTCCTTGAG -3.18 106.28 2.06
hAPP CCGCCACAGCAGCCTCTG AAATGGACACCGATGGGTAGTGAA -3.507 92.82 1.93
hBDNF CGAGACCAAGTGCAATCC TTATGAATCGCCAGCCAAT -3.282 101.69 2.02
hDGKB GATTCCAATTATTACGAAGCACTA CAAGTCATAGGTCACTGATACA -3 115.08 2.15
hDOCK4 GGCAGTGAGCAGTTGAAT GTGGGCTAACAGAATCTCTTAA -3.41 96.45 1.96
hDyrk1a TGGCAGTTCTTGTCAGTTGGG TGGCAAGGTCATAAGGCATTCC -3.554 91.15 1.91
hENSA AGTATGAATTAGGGCTTGGA GCTACTCCACTTCCTTCC -3.12 109.18 2.09
hFBXW7 ACACATTCCTTGGAACAGA CTAAGACTGACCAGCAACT -3.6 89.57 1.90
hGAP43 GCAATGTTCCGTTCATCTGAG GCCTTAGAGCCGCAAGTT -3.37 98.06 1.98
hGAPDH AATGAAGGGGTCATTGATGG AAGGTGAAGGTCGGAGTCAA -3.493 93.32 1.93
hHOMER1 CATCCACAAGTCATAATTAGGTT TCGCTTCAAGTCCACATG -3.179 106.33 2.06
hKCC2 TCCTTCAGTAGACCTCCCT CACAGCCCATCACATCAG -3.446 95.07 1.95
hNAP1L1 GAGTGTTAATGGATTATTGTGTT GATGCTTAGTTAATGGAGGTTA -3.49 93.43 1.93
hNKCC1 GCTCTATCTAAGGACCTACCACCA AGGCACTGAAGTACCATTCTGGAG -3.453 94.81 1.95
hPTTGIP TCTGTAAGGTCGGTCTTC AATTAAGGCACTCCAAGC -2.849 124.39 2.24
hRABEP2 GCTTGCTGTTGCCATCTG TGTGCTCTCCTGAGTCCAT -3.19 105.82 2.06
hRAN TGCCACCTCATTATTATCT TTAAACTGCCACATTCAC -2.95 118.26 2.18
hRERE ACACTCGGATTTGCTACG AGAACACAGAAGTCACGATT -3.82 82.71 1.83
hRLF GAGCCTTCAGAGCACTTA GTTCACTGTCATTCACCATAT -3.52 92.34 1.92
hSEMA4D TTGCTCATCTTCAACTTGT TTTGTTCTTAACCCTCTCC -3.18 106.28 2.06
hSTAT3 AATCTCCTACTTCTGCTATC CTCAGAGAACACATCCTTA -3 115.44 2.15
hTAXIBP1 ATCAGGGTCAGTCTTTGG AATCTAGCACACTAATACATACAC -3.4 96.84 1.97
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